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Developing Statistical Methods for Incorporating Complexity in Association Studies
Cameron Palmer
Genome-wide association studies (GWAS) have identified thousands of genetic variants associ-
ated with hundreds of human traits. Yet the common variant model tested by traditional GWAS
only provides an incomplete explanation for the known genetic heritability of many traits. Many di-
vergent methods have been proposed to address the shortcomings of GWAS, including most notably
the extension of association methods into rarer variants through whole exome and whole genome
sequencing. GWAS methods feature numerous simplifications designed for feasibility and ease of
use, as opposed to statistical rigor. Furthermore, no systematic quantification of the performance
of GWAS across all traits exists. Beyond improving the utility of data that already exist, a more
thorough understanding of the performance of GWAS on common variants may elucidate flaws not
in the method but rather in its implementation, which may pose a continued or growing threat to
the utility of rare variant association studies now underway.
This thesis focuses on systematic evaluation and incremental improvement of GWAS modeling.
We collect a rich dataset containing standardized association results from all GWAS conducted on
quantitative human traits, finding that while the majority of published significant results in the
field do not disclose sufficient information to determine whether the results are actually valid, those
that do replicate precisely in concordance with their statistical power when conducted in samples
of similar ancestry and reporting accurate per-locus sample sizes. We then look to the inability
of effectively all existing association methods to handle missingness in genetic data, and show that
adapting missingness theory from statistics can both increase power and provide a flexible framework
for extending most existing tools with minimal effort. We finally undertake novel variant association
in a schizophrenia cohort from a bottleneck population. We find that the study itself is confounded
by nonrandom population sampling and identity-by-descent, manifesting as batch effects correlated
with outcome that remain in novel variants after all sample-wide quality control. On the whole,
these results emphasize both the past and present utility and reliability of the GWAS model, as well
as the extent to which lessons from the GWAS era must inform genetic studies moving forward.
Contents
List of Figures iv
List of Tables vi
Acknowledgments vii
1 Introduction 1
2 Statistical Correction of the Winner’s Curse Explains Replication Variability in
Quantitative Trait Genome-Wide Association Studies 8
2.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
2.2 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
2.3 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
2.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
2.4.1 Paper Quality Control . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
2.4.2 Paper Characteristics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
2.4.3 Replication Rates, by Paper . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
2.4.4 Sample Size and Ancestry Explain Replication Inconsistency . . . . . . . . . 19
2.4.5 Functional Enrichment in Replicated Variants . . . . . . . . . . . . . . . . . . 23
2.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.6 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.7 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.7.1 Notation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.7.2 Data Collection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
i
2.7.3 Winner’s Curse Correction . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
2.7.4 Independence of Loci . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
2.7.5 Definition of Replication . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
2.7.6 Power to Replicate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
2.7.7 Poisson Binomial Distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
2.7.8 Sample Ancestries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
2.7.9 Functional Annotation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
3 Bias Characterization in Probabilistic Genotype Data and Improved Signal De-
tection with Multiple Imputation 42
3.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
3.2 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
3.3 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
3.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
3.4.1 Imputation Accuracy by Genotype, Frequency, and Quality . . . . . . . . . . 45
3.4.2 Imputation Probability Consistency . . . . . . . . . . . . . . . . . . . . . . . 49
3.4.3 Signal Enrichment with Multiple Imputation . . . . . . . . . . . . . . . . . . 51
3.4.4 MI Changes the Null Distribution of Variants . . . . . . . . . . . . . . . . . . 51
3.4.5 Extensibility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
3.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
3.6 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
3.7 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
3.7.1 Study Datasets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
3.7.2 Sample Quality Control . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
3.7.3 Prephasing and Genotype Imputation . . . . . . . . . . . . . . . . . . . . . . 63
3.7.4 Standard Analysis Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
3.7.5 Statistical Missingness Theory . . . . . . . . . . . . . . . . . . . . . . . . . . 64
3.7.6 Multiple Imputation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
3.7.7 Meta-Analysis of Multiple Imputation . . . . . . . . . . . . . . . . . . . . . . 66
4 Detecting Novel Variation in an Ashkenazi Jewish Schizophrenia Cohort 67
4.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
ii
4.2 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
4.3 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
4.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
4.4.1 Sample Characteristics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
4.4.2 Variant Quality Stratification . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
4.4.3 Novel Variant Stratification . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
4.4.4 Residual IBS Stratification at Doubletons . . . . . . . . . . . . . . . . . . . . 77
4.4.5 Novel Variant Burden Testing: Fisher/CMH . . . . . . . . . . . . . . . . . . . 81
4.4.6 Novel Variant Burden Testing: GMMAT . . . . . . . . . . . . . . . . . . . . . 82
4.4.7 Uncalibrated Type I Error Rates . . . . . . . . . . . . . . . . . . . . . . . . . 82
4.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
4.6 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
4.7 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
4.7.1 Sample Characteristics and Sequencing . . . . . . . . . . . . . . . . . . . . . 93
4.7.2 Cryptic Relatedness . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
4.7.3 Variant Quality Stratification Testing . . . . . . . . . . . . . . . . . . . . . . 94
4.7.4 Sequencing Call Rate Stratification Testing . . . . . . . . . . . . . . . . . . . 94
4.7.5 Novel Variant Selection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
4.7.6 Functional Annotation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
4.7.7 Fisher and Cochran-Mantel-Haenzel Tests . . . . . . . . . . . . . . . . . . . . 95
4.7.8 Extended Models of Burden Testing . . . . . . . . . . . . . . . . . . . . . . . 96
5 Conclusion 97
Bibliography 100
Appendix: Full Citation List for Chapter 2 111
iii
List of Figures
2.1 Schematic of the Winner’s Curse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
2.2 GWAS Replication by Paper and Journal . . . . . . . . . . . . . . . . . . . . . . . . 17
2.3 GWAS Replication by Paper and Publication Date . . . . . . . . . . . . . . . . . . . 18
2.4 Receiver Operating Characteristic for Debiasing Process . . . . . . . . . . . . . . . . 20
2.5 Effect of Ancestry and Sample Size on Nominal Replication Prediction . . . . . . . . 21
2.6 Effect of Ancestry and Sample Size on Bonferroni Replication Prediction . . . . . . . 22
2.7 GWAS Replication by Signal Strength . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.8 GWAS Replication by Signal Strength: All Studies . . . . . . . . . . . . . . . . . . . 26
2.9 GWAS Replication by Signal Strength: Replication in Same Ancestry . . . . . . . . 26
2.10 GWAS Replication by Signal Strength: Replication in Different Ancestry . . . . . . 27
2.11 GWAS Replication by Signal Strength: Study in European Ancestry . . . . . . . . . 27
2.12 Chromosomal Distribution of Analyzed Loci . . . . . . . . . . . . . . . . . . . . . . . 29
2.13 Chromosomal Distribution of Bonferroni-replicated Loci . . . . . . . . . . . . . . . . 30
3.1 IMPUTE2 Dosage Performance by r2 and Frequency . . . . . . . . . . . . . . . . . . 46
3.2 minimac3 Dosage Performance by r2 and Frequency . . . . . . . . . . . . . . . . . . 47
3.3 IMPUTE2 Quality Distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
3.4 minimac3 Quality Distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
3.5 IMPUTE2 Best-Guess Performance by r2 and Frequency . . . . . . . . . . . . . . . . 48
3.6 IMPUTE2 Probability Consistency by RSQ . . . . . . . . . . . . . . . . . . . . . . . 49
3.7 IMPUTE2 Probability Consistency by Frequency . . . . . . . . . . . . . . . . . . . . 50
3.8 BMI AUROC Improvement with MI . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
3.9 Null Distribution Shifts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
iv
3.10 Mean Convergence for MI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
3.11 Variance Convergence for MI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
4.1 Genome-wide All-Variant Quality Associated with Outcome . . . . . . . . . . . . . . 71
4.2 IBS by Schizophrenia Affectation Status, All Variants . . . . . . . . . . . . . . . . . 72
4.3 Genome-wide Pass-Variant Quality Shows Reduced Association with Outcome . . . 73
4.4 Genome-wide Full-QC Variants Show No Association with Outcome . . . . . . . . . 74
4.5 IBS by Schizophrenia Affectation Status, Filtered Variants . . . . . . . . . . . . . . . 75
4.6 Novel Variants Remain Associated with Outcome . . . . . . . . . . . . . . . . . . . . 76
4.7 Novel Loss of Function Singletons Stratified by Cohort . . . . . . . . . . . . . . . . . 78
4.8 Novel Synonymous Singletons Stratified by Cohort . . . . . . . . . . . . . . . . . . . 79
4.9 Comparative Allele Count Distributions . . . . . . . . . . . . . . . . . . . . . . . . . 83
4.10 Null Inflation Under Fisher Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
4.11 Rare Variant Allele Loading in Imbalanced Sample . . . . . . . . . . . . . . . . . . . 86
v
List of Tables
1.1 Example GWAS Replication Counts . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
2.1 Publication Venue for Significant, Replicated qtGWAS . . . . . . . . . . . . . . . . . 13
2.2 Publication Venue for Significant qtGWAS . . . . . . . . . . . . . . . . . . . . . . . . 14
2.3 QC Process for All qtGWAS Papers . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
2.4 Ancestry Distribution of All GWAS Samples . . . . . . . . . . . . . . . . . . . . . . 16
2.5 Replication Prediction by Strength of Signal . . . . . . . . . . . . . . . . . . . . . . . 25
4.1 Distribution of Novel Variants by Functional Class . . . . . . . . . . . . . . . . . . . 70
4.2 Distribution of Doubletons by Functional Class . . . . . . . . . . . . . . . . . . . . . 80
4.3 Fisher/CMH Test for Novel Functional Variants . . . . . . . . . . . . . . . . . . . . . 81
vi
Acknowledgments
I would like to acknowledge advisor Dr. Itsik Pe’er; Committee Chair Dr. Tuuli Lappalainen; Com-
mittee Members Dr. Shuang Wang, Dr. Iuliana Ionita-Laza, and Dr. Guy Sella, for their guidance
and evaluation of this project.
For the use of their genetic and trait data in the imputation quality study (Chapter 3), I would
like to acknowledge the anonymous individuals who participated in the Health ABC (Health, Aging,
and Body Composition) and NFBC66 (Northern Finnish Birth Cohort, birth year 1966) studies. For
the use of their genetic and trait data in the schizophrenia rare variant study (Chapter 4), I would





The past decade of human genetics has been dominated by the success of the genome-wide association
study (GWAS). The GWAS model prioritizes the common single nucleotide polymorphism (SNP)
as the most likely causal agent of heritable variation in complex traits. While importantly a model
born of convenience, the Common Trait (or Disease)/Common Variant hypothesis [1] has proven a
remarkably effective representation of genetic causality. Tens of thousands of associations have been
detected for hundreds of common traits [2, 3]. The technology continues to improve in both genome
coverage and price; modern GWAS bear little resemblance to the original studies in the mid–2000s,
and continue to expand into traits and populations left out of the initial wave of study.
The inability of GWAS to consistently explain the entirety of genetic heritability [4, 5, 6] of
traits has been attributed to many different possible causes. The simplest explanation suggests
that the complex genetic architecture of polygenic human traits manifests in potentially thousands
of common variants of low effect. Under this model, missing heritability is simply a function of
insufficient power: collecting more samples will eventually address the issue. Evidence supporting
this explanation has been most thoroughly characterized for common anthropometric traits (height,
body mass index as a proxy for adiposity, etc.): statistical models [7, 8] project the total genetic
heritability of these traits captured by GWAS to be more than 80% of the total heritability for
the trait. These models remain, however, projections: the actual genetic causes have not been
specifically identified, but their behavior has been characterized en masse. The implications of the
tendency of GWAS to characterize patterns but not individual targets will be discussed more in
Chapter 2.
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Perhaps the most widely accepted explanation for Missing Heritability is simply that GWAS
are simply looking in the wrong place: the Common Trait/Common Variant hypothesis ignores the
substantial contribution of rare genetic variation to common heritable traits. The contribution of
rare variants to human traits is now well-established in many reliable studies (for example among
many others, [9, 10, 11]). This evidence is largely the motivation behind and goal of the transition
of genetics from array-based technology to exome and genome sequencing.
Additional limitations of the GWAS model abound. Association studies carry with them a series
of simplifying assumptions. In the vast majority of studies, a cross-sectional trait is tested for
marginal association with a single common SNP by linear or logistic regression. The only major
deviation from this model has come with the era of rare variant testing, as minor allele counts for
rare variants (below 1% of alleles present in a sample) are insufficient for marginal testing, and thus
must be combined in some form of burden test (discussed further in Chapter 4). Testing independent
sites for a single collection of a phenotype leads to acceptable statistical complexity when from 5 ·105
to 4 ·107 variants are tested in an individual study. Yet that is the only reason for such assumptions:
there is no particular reason to believe that this model is an accurate general representation of
meaningful biological characteristics or processes. The heritability estimated from a genetic model
is only as accurate as the model itself.
It is important to note that the projections of explained heritability in [7, 8] differ substantially
from the metrics cited in [12], when the Missing Heritability issue first reached prominence at the
beginning of this decade. For human height, the proportion of explained genetic heritability was cited
as approximately 6.25% in 2010; as of 2015, that number was closer to 85%. There are important
caveats to the 2015 number: closer to 25% of explained genetic heritability is attributable to specific
loci, and the remainder is based on statistical models of bulk behaviors of the rest of the genome.
Furthermore, some genetic heritability is still unexplained, and this single result is based on the
combined effort and resources of a nontrivial percentage of the entire field. Yet it is difficult to
describe this change as anything but promising, and certainly supportive of the general model of
GWAS at large.
This dissertation can be framed in light of this consideration: a reevalution of the field of GWAS,
with the benefit of improved statistics and retrospect, shows that the field at large is in fact sub-
stantially more effective at explaining human genetic heritability than first thought. We ask what
other aspects of GWAS might be significantly improved with consideration and standardization. We
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present these results in the form of three vignettes: methods and aspects of the association study
methodology upon which we can significantly improve with formal analysis.
An early concern in the design of this study was to provide metrics regarding the reliability of
the GWAS model: to quantify the vague assessment of whether a GWAS study is typically rigorous
and informative. The very idea of assessing the “reliability” of GWAS is complicated, and requires
some details of the GWAS study design. The standard genome-wide association study has a two-
stage design. In the first (discovery) stage, some number of cohorts, consisting of human subjects
with phenotype and epidemiological covariate data, as well as DNA assayed on one of many possible
GWAS platforms, are tested for association between each assayed variant in turn and a phenotype
of interest. In the second (replication) stage, some proportion of strongly associated variants are
tested in an “independent” set of cohorts. The precise definition of replication varies from study to
study (see Chapter 2). The use of Bonferroni corrected p-values for significance testing is prevalent,
wherein replication is defined as either:
1. replication p-value exceeding Bonferroni corrected α for number of attempted replications; or
2. meta-analyzed discovery and replication p-value exceeding Bonferroni corrected α for number
of attempted discoveries
Regardless of the precise definitions used, the discovery process in GWAS is subject to regression
to the mean [13], colloquially called the “Winner’s Curse.” In short, the process by which the
most significant variants are selected for either replication or publication induces an upward bias in
the estimated magnitude of effect of the “winning” variants, as the sampling error distribution for
variants near the selection cutoff are probabilistically truncated. While significant theoretical work
has been conducted to create methods of correcting discovery effect estimates [14, 15, 16, 17, 18,
19, 20], these have not enjoyed widespread adoption by the field at large. Rather, studies rely on
large sample sizes and the relative cost efficiency of in silico replication lookups to accommodate
aberrantly high replication failure. Thus do we see results such as those in Table 1.1.
What is ultimately deceptive about these extreme examples is that there is nothing intrinsically
wrong with these studies. The power calculations are inherently biased, as in none of these cases (nor
indeed in any of the other 327 papers from which these data are taken) did the authors attempt to
prospectively adjust for the Winner’s Curse. As such, there is no evidence from these data that these
GWAS were inefficient at replication. Nevertheless, the psychological impact of failing to replicate
3
PMID Attempted Expected Observed
18846228 21 21 0
20010834 30 26 5
20887962 32 32 1
22021425 84 81 5
23669352 67 59 3
Table 1.1: Exemplar replication performances from actual studies. PMID: PubMed ID code for
particular study. Attempted: number of variants brought forward from discovery into replication.
Expected: MLE number of replications based on reported power to replicate at Bonferroni thres-
hold from the published study. Observed: number of replications amongst the attempted variants,
computed as number of variants surpassing Bonferroni-corrected replication p-value. See Chapter 2
for more on these data.
thousands of apparent signals should not be underestimated. Such results may leave the reader with
the impression that GWAS consistently fail to replicate, and these papers make no direct effort to
address this concern.
The unfortunate result of these observations is that it is simply not possible to make a general
statement about whether GWAS perform in practice as they are expected to in theory. To make
such a statement, one would need to harvest GWAS discovery and replication data from hundreds
of studies across dozens of journals, standardize the contents, apply a Winner’s Curse correction
algorithm to those data, and then using uniform definitions of replication, fit models for how well
such studies were predicted to replicate according to their apparent statistical power. No such
undertaking has been attempted, to our knowledge: at most, the studies showcasing methods to
correct the Winner’s Curse typically deploy their method on no more than six selected GWAS [17,
20], which even ignoring selection bias does not represent a sample sufficiently powered to render
conclusions about the field as a whole.
Thus, as discussed at length in Chapter 2, we have undertaken just the sort of analysis described
above. We have focused in particular on quantitative (normally-distributed) traits, for which less
theory has been developed and which have received negligible attention in existing evaluation studies.
We show two major results. The first is that the field at large underreplicates using na¨ıve estimates
of power based on cursed discovery data, but that underreplication is completely abrogated by (1)
correcting the Winner’s Curse, and excluding studies that (2) conduct discovery and replication in
cohorts of distinct ancestry, as well as those that (3) incorrectly report per-variant sample sizes.
While the first two factors are widely acknowledged, incorrect sample sizes (in particular, uniformly
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overestimated sample sizes based on the maximum possible sample size) are a component of our
second major finding from the study: more than half of published quantitative trait GWAS studies
report insufficient information to actually prove their replication performance. Lack of uniform
reporting standards in the field have created a vast corpus of unproven claims. This is an urgent
problem that needs to be addressed.
Moving beyond quantification of existing results, we consider particular components of the GWAS
study design that invite reconsideration and rigorous treatment. An integral component of any
GWAS of the last decade is the process of genotype imputation. As discussed at length in Chapter 3,
imputation is the process of probabilistically estimating untyped variants in a sample using external
reference data. Imputation methods have received substantial attention in the GWAS era ([21, 22],
among dozens). Less widely discussed is the impact these methods have on the choice of downstream
statistical tests. As a rule, statistical genetics methods are not capable of directly operating on
probabilistic genotypes, without some form of approximation that reduces the available information
concerning genotypic uncertainty. But calling genotypes from imputed probabilities is a problematic
endeavor, as genotype imputation introduces characteristic biases and high error rates, as we report
in some depth in Chapter 3.
Data missingness and uncertainty have been thoroughly characterized in the general statistics
literature [23]. In that context, the method of Multiple Imputation (MI; upon which genotype
imputation is in fact modeled) represents the formally correct method of handling probabilistic data
in statistical tests. While there are periodic efforts to use MI in particular contexts, it has not been
formally evaluated in the context of probabilistic genotypes. We therefore have fully characterized
MI in the context of GWAS association. We also deem that the primary hurdle towards using MI
in genomics is not theoretical but rather practical: each individual analyst and statistician needs
to know of and implement MI from scratch, leading to the hodgepodge of approximate methods
currently in use. To address this issue, we have created a software tool [24] that streamlines the
process of integrating existing analysis tools with the MI regime. We hope that such a software
interface may provide some impetus to adopting more appropriate missingness handling in future
work.
Finally, any discussion of the state of association studies would be incomplete without conside-
ration of rare variants. The initial wave of association studies made use of DNA microarrays, and
as such entirely avoided consideration of variation below appreciable frequencies in reference popu-
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lations. Yet the advent of the Missing Heritability problem [4, 5, 6], combined with ever-decreasing
costs of exome and genome sequencing, rapidly moved rare variation to the forefront of statistical
genetics.
Even with the technical restriction on sequencing alleviated, rare variation offers unique challen-
ges for both quality control and statistical analysis. The process of sequence calling relies on both
prior probabilities of variation and observed numbers of reads of a given alternate allele [25]; both
of these parameters are most difficult to specify at rare and novel loci. Furthermore, even assuming
high quality calls, standard analysis tools such as regression cannot reliably estimate correlations
between variation and outcome with so few observations of the minor allele. This observation has
led to the proliferation of burden tests [26, 27, 28, 29], in which pools of rare variation are combined
under various models to attempt to increase power to detect association.
Formal burden tests are exceedingly useful, but even so require substantial resources to generate
sample sizes sufficient to create well-powered tests. There is the potential to lessen these demands
by creative selection of study sample. Allele frequency may differ substantially between populations
of restricted mating over short numbers of generations, independent of selective pressure. Rare
variation in one population may be substantially more common, and thus easier to ascertain, in
another population of different demographic history [30]. In particular, bottleneck populations,
in which recent population contraction and expansion have greatly restricted the effective number
of haplotypes in a reproductive group, offer a particularly attractive opportunity for efficient rare
variant testing.
In Chapter 4, in the context of a larger consortium case/control study of schizophrenia in Ashke-
nazim, we conduct novel variant burden testing as a first approach towards characterizing the rare
variant burden of this cohort. Other collaborators recently conducted a similar study [31] of Alz-
heimer’s disease in Ashkenazim, so we take their statistical model as our initial approach. While
this reference study was able to detect a strong preferential burden of rare, functionally-annotated
variants in their case samples, we find instead in this case a complicated series of stratification effects
ultimately attributable to nonrandom sampling from hidden pedigrees and nonrandom sequencing of
individuals with respect to both case status and relatedness of samples. Furthermore, in calibrating
our statistical model, we find that published work on functional novel burden testing is subject to
substantially miscalibrated Type I error, due to improprieties in selecting reference groups of novel
variation to serve as a null control. While disappointing from the perspective of biological discovery,
6
the realization that effective IBD of samples may cause local distortions in singleton and doubleton
call rates is important and provides essential guidance for sequencing study design in the future.
Taken as a whole, these vignettes of statistical genetics provide a meaningful contribution to
the field. They broadly suggest that a large variety of highly technical issues remain to be resolved
to improve the GWAS study model. One would hope that many of the observations made herein










Genome-wide association studies (GWAS) have identified hundreds of SNPs responsible for variation
in human quantitative traits. However, genome-wide-significant associations often fail to replicate
across independent cohorts, in apparent inconsistency with their apparent strong effects in discovery
cohorts. This limited success of replication raises pervasive questions about the utility of the GWAS
field. We identify all 332 studies of quantitative traits from the NHGRI-EBI GWAS Database with
attempted replication. We find that the majority of studies provide insufficient data to evaluate
replication rates. The remaining papers replicate significantly worse than expected (p < 10−14),
even when adjusting for regression-to-the-mean of effect size between discovery- and replication-
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cohorts termed the Winner’s Curse (p < 10−16). We show this is due in part to misreporting
replication cohort-size as a maximum number, rather than per-locus one. In 39 studies accurately
reporting per-locus cohort-size for attempted replication of 707 loci in samples with similar ancestry,
replication rate matched expectation (predicted 458, observed 457, p = 0.94). In contrast, ancestry
differences between replication and discovery (13 studies, 385 loci) cause the most highly-powered
decile of loci to replicate worse than expected, due to difference in linkage disequilibrium.
2.2 Summary
The majority of associations between common genetic variation and human traits come from genome-
wide association studies, which have analyzed millions of single-nucleotide polymorphisms in millions
of samples. These kinds of studies pose serious statistical challenges to discovering new associations.
Finite resources restrict the number of candidate associations that can brought forward into valida-
tion samples, introducing the need for a significance threshold. This threshold creates a phenomenon
called the Winner’s Curse, in which candidate associations close to the discovery threshold are more
likely to have biased overestimates of the variant’s true association in the sampled population. We
survey all human quantitative trait association studies that validated at least one signal. We find
the majority of these studies do not publish sufficient information to actually support their claims
of replication. For studies that did, we computationally correct the Winner’s Curse and evaluate
replication performance. While all variants combined replicate significantly less than expected, we
find that the subset of studies that (1) perform both discovery and replication in samples of the
same ancestry; and (2) report accurate per-variant sample sizes, replicate as expected. This study
provides strong, rigorous evidence for the broad reliability of genome-wide association studies. We
furthermore provide a model for more efficient selection of variants as candidates for replication, as
selecting variants using cursed discovery data enriches for variants with little real evidence for trait
association.
2.3 Introduction
Genome-wide association studies (GWAS) have identified thousands of genetic variants associated
with complex human traits [3]. GWAS are most commonly two-stage designs, with a discovery
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study followed up by (possibly several) internal replication studies on independent samples. Due to
the number of variants tested in the typical association study, replication is only attempted for a
small fraction of the discovered variants exceeding a p-value threshold adjusted for 106 independent
tests. The tradeoff between study power per-variant and resources, along with the strategy of testing
millions of variants for association, leads to study designs where many associated variants of low
effect size [32] are underpowered to be detected.
The Winner’s Curse (WC) is the systematic overestimation of effects ascertained by thresholding.
This phenomenon is induced by ascertainment of the most significant GWAS signals for reporting:
introducing a threshold on statistical significance means that the selected set of signals will prefe-
rentially contain variants whose effects are overestimated in a particular study sample due to chance
noise (Figure 2.1). This tendency of studies to overestimate their association with a phenotype in the
discovery cohort might cause them to replicate at an unexpectedly low rate, increasing the apparent
unreliability of results from the field. This study relies on computationally correcting this biased
overestimate of effect size, in order to produce accurate estimates of the chances for replication.
Several models for directly estimating bias in effect estimates have been developed. Parametric
models, based predominantly on the theory established in [18], generate a maximum likelihood
estimation of the effect estimate based on the impact of introducing a p-value threshold into the
reported list of variants; thus, test statistics close to the threshold tend to be biased more severely
than those more substantially exceeding the threshold. Alternatively, nonparametric bootstrap
correction of the Winner’s Curse using individual-level genetic data [20] has been implemented.
Evaluation of these models for binary [17, 15] and quantitative [14] traits has been limited to
simulations and a small number of studies, without establishing the importance of WC-correction
to GWAS study design.
Further complicating matters, there is no single accepted standard for successful internal re-
plication of a variant in a GWAS. Across the GWAS considered in this study we have observed
several definitions of replication. The variability of these definitions leads to differing standards of
“replicating signal” in the literature, and complicates an evaluation of replicability across the field.
Variants found to be trait-associated in GWAS are not necessarily causal [33], due to linkage
disequilibrium (LD) between common variants. Causal variants are expected to replicate, whereas
significantly-associated noncausal variants will only replicate if they remain linked to a causal variant
in a replication study. The predicted rate of replication for noncausal variants is not trivial, as in
10
Figure 2.1: Schematic diagram representing the bias from the Winner’s Curse. A SNP with
fixed frequency, sample size, and phenotypic variance explained was repeatedly drawn at random,
and the accompanying standard normal trait was simulated. The apparent effect of SNP on trait
was estimated exclusively from simulations exceeding progressively more stringent replication α.
X-axis: replication α; Y-axis: estimated SNP effect from linear regression. Two simulations with
different effect estimates (horizontal lines) are shown. The height of the vertical lines corresponds
to the average bias (curse) introduced by discovery prioritization.
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general the causal variant in a locus is unknown and may not be assayed in the study. In particular,
more GWAS now attempt discovery and replication in samples of distinct ancestries, which are ex-
pected to have substantially different LD patterns across much of the genome. Moreover, even when
LD between a hidden causal variant and its observed proxy are comparable across replication and
discovery, there remains an open question as to whether, and in what contexts, SNPs are expected
to have comparable effect in different ancestral backgrounds; existing work, in particular using the
same database from this study [34], has provided inconclusive results that may be confounded by
both the Winner’s Curse and a preponderance of false positive variants.
In this study [35] we seek to evaluate the replicability of SNPs in genome-wide association studies
across the field of human quantitative trait genetics. We specifically consider quantitative trait
studies as they are underrepresented amongst theoretical work for correcting the Winner’s Curse,
and represent a meaningful subset of the field (33% of papers considered) that is still sufficiently small
that we may feasibly evaluate all existing studies. The NHGRI-EBI GWAS Catalog [2, 3] provides a
reasonably complete database of publications claiming to report genome-wide significant associations
between variants and human traits. We use this catalog as a tool to identify the vast majority of
papers in the field. Using only summary data reported in these papers, we modeled the Winner’s
Curse in all papers providing enough information to actually support their claims of replication. We
recomputed their replication rates according to the nominal and Bonferroni standards of replication,
thus introducing a standardized regime to make generalizations about replication efficiency across
all studies. Together, we obtain reliable metrics to evaluate the state of human quantitative trait
genetics as a reproducible scientific domain.
2.4 Results
2.4.1 Paper Quality Control
We considered all 332 GWAS papers for quantitative-traits in the database [2, 3] from journals
we deemed pertinent to human genetics (see Table 2.1, Table 2.2) that attempted replication of
discovered variants. We filtered this pool, requiring study design of strict thresholding, reports of
data needed to calculate bias in effect sizes [18], and related consistency criteria (see Methods, Table
2.3). This reduced the pool to k = 100 post-QC papers (30%) for analysis.
The above counts consider each paper as a functional unit. In some cases, a single paper will
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Analyzed Excluded
Am J Hum Genet 8 23
Am J Med Genet B Neuropsychiatr Genet 2 2
BMC Med Genet 3 3
Circ Cardiovasc Genet 4 12
Front Genet 1 0
Gene 1 1
Genet Epidemiol 1 1
Hum Genet 3 7
Hum Mol Genet 24 48
J Med Genet 1 5
Nat Genet 26 48
PLoS Genet 18 31
PLoS One 6 21
Science 2 2
Total: 100 204
Table 2.1: Distribution of papers across journals, for journals that had at least one article
with sufficient information for analysis. The full distribution of all journals analyzed in the
study, including those with all papers excluded, is in Table 2.2.
publish multiple GWAS: that is, multiple phenotypes will be analyzed in the same paper. The 100
papers passing QC correspond to 134 “studies,” with 79 papers containing only a single study, and
the remainder having fewer than 6 studies each. As these additional studies typically contribute a
very small number of variants to our analysis, we proceed with the paper count as a more honest
reflection of the scope of our analysis.
2.4.2 Paper Characteristics
The sum of discovery sample sizes across all analyzed papers reaches approximately 1.8 million non-
unique individuals. The majority (88%) of this cumulative count have European ancestry, framing
the analysis in the context of this group. This 6.7-fold over representation of European ancestry is
part of uneven sampling of world populations in GWAS (Table 2.4).
The tally of variants these papers attempted to replicate lists 2691 non-unique variants, each
passing the corresponding paper-specific p-value threshold in its discovery cohort. Many of these
papers include linked variants on this list, introducing partial redundancies. We filtered dependent
variants (Methods) to obtain 1652 loci for analysis, independent within each paper.
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Analyzed Filtered
Am J Hum Genet 8 23
Am J Med Genet B Neuropsychiatr Genet 2 2
Ann Hum Genet 0 1
BMC Genomics 0 1
BMC Med Genet 3 3
BMC Med Genomics 0 1
Circ Cardiovasc Genet 4 12
Eur J Hum Genet 0 3
Front Genet 1 0
G3 (Bethesda) 0 1
Gene 1 1
Genes Brain Behav 0 1
Genes Immun 0 1
Genet Epidemiol 1 1
Genomics 0 1
Genomics Inform 0 1
Hum Genet 3 7
Hum Mol Genet 24 48
Immunogenetics 0 2
J Hum Genet 0 2
J Med Genet 1 5
Nat Genet 26 48
Nature 0 7
PLoS Genet 18 31
PLoS One 6 21
Pharmacogenet Genomics 0 1
Pharmacogenomics 0 1
Pharmacogenomics J 0 1
Science 2 2
Twin Res Hum Genet 0 3
Total: 100 232
Table 2.2: Distribution of quantitative trait GWAS papers across journals, for journals that
had at least one article annotated as ”attempting replication” in the NHGRI-EBI GWAS Database

































































































































































































































































































































































































































































































































































































































































European East Asian African African American
Totals 1601628 135472 1226 80006
Rate in GWAS (percent) 88.08 7.45 0.07 4.4
Rate in Population (percent) 13.3 59.8 13.1 0.5
Enrichment in GWAS (percent) 670.8 12.5 0.51 821.6
Table 2.4: Ancestry distribution of samples included in GWAS. Rows are as follows: (1) “To-
tals”: number of samples of a given ancestry in analyzed papers, with redundancy between studies
published multiple times; (2) “Rate in GWAS”: percentage of total samples considered that were of
this ancestry; (3) “Rate in Population”: percentage of world’s population that is of this ancestry;
(4) “Enrichment in GWAS”: relative over (or under) representation of ancestry in GWAS relative
to its rate in the world. Ancestry labels are approximations with the standard correspondences to
HapMap2 reference samples (European = CEU, East Asian = JPT+CHB, African = YRI); here,
“African American” denotes samples reported with that nomenclature, which typically corresponds
to 80:20 admixture between ancestral sub-Saharan African and Western European genetics [36]. All
of these equivalences are oversimplifications but correspond to assumptions widely used in the field.
Counts are computed from totals across all papers analyzed in this study, not adjusting for duplicate
uses of the same datasets across multiple studies. Total sample sizes are maximum counts of samples
assuming no per-genotype missingness is present. The totals are rounded to the nearest integer as
several imputed studies reported nonintegral sample sizes. Row 3 percentages in world population
are approximations based on demographic data from 2014-2015 [37, 38].
2.4.3 Replication Rates, by Paper
At a nominal threshold α = 0.05, we observe 793/1652 independent loci to replicate (48%) across
100 papers. Based on the raw effect sizes reported in the discovery cohort, we would have ex-
pected 1498 loci to replicate (90.7%), significantly more than observed (two-tailed Poisson binomial
p = 4.2 · 10−15). Statistical correction of WC leads to a prediction of 888 replicated loci (53.8%),
7-fold closer but still significantly more than observed (p < 3 · 10−16). Replacing the nominal thres-
hold by Bonferroni-adjusted thresholds (α = 0.05# loci attempted in a particular paper ), we observe 519
replicated loci (31.4%), significantly different than both raw (p = 3.3 · 10−14) and WC-corrected
(p = 9.0 · 10−15) replication predictions of 1235 (74.8%) and 610 (36.9%) loci, respectively.
Predicting WC-corrected replication rates per paper (Poisson binomial distribution), we observe
excess of papers both over- and under-performing their respective expectations (Figure 2.2A). This
excess significantly correlates with publication venue (Figure 2.2B). Specifically, papers in higher
impact journals tended to over-replicate, consistent with publication bias [39, 40, 41] (Discussion).
We also consider weak correlation between paper replication behavior and date of publication in
Figure 2.3.
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Figure 2.2: Expected and observed replication rate per publication, stratified by journal.
Top panel (A): predicted versus expected replication for each paper. Each paper is flagged as
being within 95% confidence of predicted replication rate under WC-corrected model (dots), greater
(diamonds) or lower (Xs) than expectation. X-axis: predicted number of replications in a given
paper, calculated as the sum across all loci of power to replicate based on WC-corrected discovery
effect estimates. Y-axis: observed (jittered integer) number of replications in the paper. Colors
correspond to journals. Replication is defined as a one-tailed replication p-value surpassing a per-
paper Bonferroni threshold: 0.05#loci attempted in paper . Confidence intervals defined as 95% confidence
according to Poisson binomial draws from the WC-corrected power distribution. Bottom panel (B):
distinct behaviors in journals depending on which set of papers is considered. Clusters correspond
to paper quality (point shapes) from top panel; confidence intervals are 95% confidence intervals
from the binomial distribution. Red lines are expected bar heights assuming that the observed paper
data correspond to the WC-corrected model.
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Figure 2.3: Expected and observed replication rate per publication aligned with publi-
cation date. Top panel (A): predicted versus expected replication for each paper, with each paper
flagged as being within 95% confidence of predicted replication rate under WC-corrected model,
greater than or less than expectation. X-axis: predicted number of replications in a given paper,
calculated as the sum across all loci of power to replicate based on WC-corrected discovery effect
estimates. Y-axis: observed number of replications in the paper. Colors correspond to publication
dates binned into six month intervals, from 2008 to 2014. Point shapes to correspondence between
observed and expected rates. Replication is defined as a one-tailed replication p-value surpassing
a per-paper Bonferroni threshold: 0.05#loci per paper . Confidence intervals defined as 95% confidence
according to Poisson binomial draws from the WC-corrected power distribution. Bottom panel (B):
papers underperforming the WC-corrected model tend to have been published later; papers over-
performing the WC-corrected model tend to have been published earlier. While these trends are
significant, they are dominated by the large number of QC-passing papers from Nature Genetics,
which possess an earlier average publication date as well as a replication rate significantly higher
than expected based on reported power.
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2.4.4 Sample Size and Ancestry Explain Replication Inconsistency
Few papers (k = 13) discovered variants in one continental ancestry and attempted replication in
another. This study design may hurt replication beyond WC due to population-specific effects,
including linkage disequilibrium. Most (48/87) remaining papers reported single sample size N for
replication across all attempted variants, not reflecting different fractions of missing data for each
variant. Note that this includes genotypes missing from association analysis, rather than unmeasured
genotypes whose analysis was conducted within the study, even if through imputation. In particular,
studies conducting meta-analysis may only obtain variant data from a subset of their contributing
cohorts, leading to large discrepancies in effective sample size per locus. This exaggerated replication
sample size overestimates power to replicate and thus inflates predicted replication rate.
The remaining 39 papers with 707 discovered loci both maintained continental ancestry across
discovery and replication while also correctly reporting per-locus N . At nominal threshold, 457 loci
(64.6%) replicate, consistent (Poisson binomial p = 0.94) with the WC-corrected prediction of 458
loci (64.8%). Considering instead the more stringent Bonferroni correction, observed replication
of 304 loci (43%) was also consistent (p = 0.14) with the 316 expected (44.7%). In both cases,
predicting replication without WC-correction fails (all p < 10−14). Considering all thresholds across
these papers, WC-correction significantly improved sensitivity over raw discovery estimates (ROC
AUC 0.785 vs. 0.582, DeLong two-tailed p < 2 · 10−16; see Figure 2.4). We thus hereafter consider
only WC-corrected estimates.
The improved fit amongst these 39 remaining papers is not explained by reduction in power to
reject fit: fit is more improved than chance expectation (based on simulations on subsets of variants
with matched power to observed; nominal replication, p < 0.001; Bonferroni replication, p < 0.001).
Furthermore, both N and ancestry filters are required for good model fit (see Figure 2.5 and Figure
2.6).
We further tested the importance of per-locus sample size reporting by repeating the replication
rate analysis on 39 papers/707 loci with correct ancestry and sample size, but instead using the
maximum available sample size for each study. Correcting the Winner’s Curse using these aberrant
sample sizes, the predicted rates of replication are no longer consistent with observed data (nominal
replication: p = 0.0495; Bonferroni replication: p = 0.000202). These results further support the
conclusion that correct per-locus sample size reporting is essential for both accurate Winner’s Curse
19
Figure 2.4: Improved prediction of replication with Winner’s Curse-corrected discovery
effect estimates. Plotted are receiver operating characteristics (ROC) for raw discovery and WC-
corrected estimates of power to nominally replicate variants in individual studies. X-axis: false
positive rate, computed as number of non-replicating variants having greater than a given power to
replicate; Y-axis: true positive rate, computed as number of replicating variants having such power.
AUC: 0.795 (WC-corrected) versus 0.579 (biased); DeLong’s two-tailed p < 2 · 10−16. Considers
studies with same ancestry in both discovery and replication and correct per-locus sample sizes, as
used in the main results.
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Figure 2.5: Improvement in fit for nominal replication prediction requires both same
ancestry replication and per-locus sample sizes. Each node corresponds to one method of
subsetting the data: all papers; papers conducting discovery and replication in the same continental
ancestry; papers reporting correct per-locus sample sizes; or papers doing both. Probabilities in
nodes correspond to two-tailed Poisson binomial fit test for prediction of nominal replication rates
after Winner’s Curse correction. Probabilities along edges correspond to the chance of randomly
seeing improvement of fit between connected nodes at least as large as observed due to loss of
power exclusively, based on 10000 simulated subsamplings from the source node matched on total
predicted power to replicate. Relative position of nodes along vertical axis corresponds to number
of loci removed in the subset.
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Figure 2.6: Improvement in fit for Bonferroni replication prediction requires both same
ancestry replication and per-locus sample sizes. Each node corresponds to one method of
subsetting the data: all papers; papers conducting discovery and replication in the same continental
ancestry; papers reporting correct per-locus sample sizes; or papers doing both. Probabilities in
nodes correspond to two-tailed Poisson binomial fit test for prediction of Bonferroni replication rates
after Winner’s Curse correction. Probabilities along edges correspond to the chance of randomly
seeing improvement of fit between connected nodes at least as large as observed due to loss of
power exclusively, based on 10000 simulated subsamplings from the source node matched on total
predicted power to replicate. Relative position of nodes along vertical axis corresponds to number
of loci removed in the subset.
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correction and verifiable replication reporting.
We next investigated the relationship between the strength of a signal and its replication rate.
We partitioned all loci across all 100 papers into deciles according to their observed replication p-
value. We then used each variant’s power to replicate within its study to predict the replication
rate within each decile. Note that, as we used deciles here, the observed and expected values should
both be 10%, within confidence bounds and rounding error.
Across all variants, the predicted replication rate per bin was not significantly different from 10%,
as expected, with the notable exception of the highest decile: the strongest signals tended to replicate
significantly less than predicted (see Figure 2.7). This deviation primarily explains why the entire
partition into deciles was significantly different than expected (χ2 goodness of fit p < 10−4). As
before, when restricting analysis to same-ancestry replication and reporting per-locus N (see Figures
2.8 through 2.11 for other subsets), replication rates became consistent with prediction, both jointly
across all decile bins (p = 0.67) as well as within each (Table 2.5). Again, this is not simply lack of
power to reject fit: the reduction in significance is beyond random expectation (p < 0.01). Several
other partitions of the data approached good fit (Table 2.5), but no more than was expected due to
reduction in power (all p > 0.05).
As before, when restricting analysis to same-ancestry replication and reporting per-locus N (see
Figure 2.8 for all papers, Figure 2.9 for same ancestry studies, Figure 2.10 for different ancestry
studies, and Figure 2.11 for the subset of same ancestry studies considering European samples),
replication rates became consistent with prediction, both jointly across all decile bins (p = 0.94) as
well as within each (Table 2.5). Again, this is not simply lack of power to reject fit: the reduction
in significance is beyond random expectation (p < 0.01). Several other partitions of the data
approached good fit (Table 2.5), but no more than was expected due to reduction in power (all
p > 0.05).
2.4.5 Functional Enrichment in Replicated Variants
Finally, we evaluated enrichment of functional annotations in detected and replicated variants. We
restrict this analysis to 56 papers which imputed their discovery samples using the HapMap2 CEU
reference panel. Variants in the CEU reference provide a null distribution for functional annotation.
Amongst all 998 loci for which replication was attempted in these papers, the observed 29 nonsyn-
onymous variants constitute 5X enrichment compared to expectation from HapMap2 (expected 6
23
Figure 2.7: Expected and observed rates of replication in replication deciles. All variants
are sorted by replication p-value and partitioned into deciles; we then compute power to replicate
the variants in each bin using effect estimates with or without the Winner’s Curse. Left panel
(A): including all papers (WC-corrected χ2 goodness of fit p < 10−4); right panel (B): including
only papers conducting discovery and replication in the same continental ancestry per variant and
reporting accurate per-locus N (WC-corrected χ2 goodness of fit p = 0.67). Improvement of fit
exceeds what is expected due to loss of power from subsetting data (p < 0.01). X-axis: upper
p-value boundary of bin; Y-axis: predicted fraction of replication within corresponding bin based on
power estimated from discovery data. Tracks correspond to predicted power to replicate using raw
discovery (red) or WC-corrected (teal) effect estimates. Error bars correspond to 95% confidence










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.8: Expected and observed rates of replication at different replication thresholds,
across all 100 papers, 1652 independent loci. X-axis: left boundary of bin on replication
threshold; Y-axis: percentage of replication within corresponding bin. Tracks correspond to actual
data in the replication study, predicted power to replicate using discovery effect estimates, and
predicted power to replicate using WC-corrected discovery effect estimates. Loci brought forward to
replication in papers were pruned to contain independent signals within (but not necessarily between)
individual papers. Error bars correspond to 95% confidence intervals around mean replication rates
as estimated across multiple loci. Left panel: including all papers; middle panel: including only
papers with accurate per-locus sample sizes; right panel: including only papers with maximal sample
sizes per variant. Including only maximum sample size regardless of per-variant missingness will
uniformly inflate replication rate estimates.
Figure 2.9: Expected and observed rates of replication at different replication thresholds,
across 87 papers conducting discovery and replication in the same ancestry, 1269 in-
dependent loci. X-axis: left boundary of bin on replication threshold; Y-axis: percentage of
replication within corresponding bin. Tracks correspond to actual data in the replication study,
predicted power to replicate using discovery effect estimates, and predicted power to replicate using
WC-corrected discovery effect estimates. Loci brought forward to replication in papers were pruned
to contain independent signals within (but not necessarily between) individual papers. Error bars
correspond to 95% confidence intervals around mean replication rates as estimated across multiple
loci. Left panel: including all papers; middle panel: including only papers with accurate per-locus
sample sizes; right panel: including only papers with maximal sample sizes per variant. Including
only maximum sample size regardless of per-variant missingness will uniformly inflate replication
rate estimates.
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Figure 2.10: Expected and observed rates of replication at different replication thres-
holds, across 13 papers conducting discovery and replication in different continental
ancestries, 383 independent loci. X-axis: left boundary of bin on replication threshold; Y-
axis: percentage of replication within corresponding bin. Tracks correspond to actual data in the
replication study, predicted power to replicate using discovery effect estimates, and predicted power
to replicate using WC-corrected discovery effect estimates. Loci brought forward to replication in
papers were pruned to contain independent signals within (but not necessarily between) individual
papers. Error bars correspond to 95% confidence intervals around mean replication rates as estima-
ted across multiple loci. Left panel: including all papers; middle panel: including only papers with
accurate per-locus sample sizes; right panel: including only papers with maximal sample sizes per
variant. Including only maximum sample size regardless of per-variant missingness will uniformly
inflate replication rate estimates.
Figure 2.11: Expected and observed rates of replication at different replication thres-
holds, across 60 papers conducting discovery and replication in individuals of European
grandparental ancestry, 976 independent loci. X-axis: left boundary of bin on replication
threshold; Y-axis: percentage of replication within corresponding bin. Tracks correspond to actual
data in the replication study, predicted power to replicate using discovery effect estimates, and pre-
dicted power to replicate using WC-corrected discovery effect estimates. Loci brought forward to
replication in papers were pruned to contain independent signals within (but not necessarily bet-
ween) individual papers. Error bars correspond to 95% confidence intervals around mean replication
rates as estimated across multiple loci. Left panel: including all papers; middle panel: including
only papers with accurate per-locus sample sizes; right panel: including only papers with maximal
sample sizes per variant. Including only maximum sample size regardless of per-variant missingness
will uniformly inflate replication rate estimates.
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loci; p < 0.0001 based on 10000 simulated resamplings of random variants matched on count and
minor allele frequency). This is due to significant enrichment of genic SNPs amongst all replica-
tion candidates (3.6X, p < 0.0001), as well as an additional enrichment of nonsynonymous variants
among them (1.5X, p = 0.0003). Variants reaching per-paper Bonferroni replication are further 1.8X
enriched in nonsynonymous exonic variants, from 2.9% across 998 attempted variants to 5.2% in 443
replicated ones (Binomial test one-tailed p = 0.0061). This change is due to enrichment of exonic
SNPs in replicated variants, with no further significant selection for functional variants (p = 0.37).
These results are not being driven by particular outliers (χ2 goodness of fit p = 0.44; Methods). Ana-
logous enrichment among nominally-replicated variants (1.3X) is not significant (Binomial one-tailed
p = 0.1447).
2.5 Discussion
This study provides the first systematic evidence of the efficacy of internal replication in the field
of quantitative trait genome-wide association studies. Overall, with important caveats, we find that
the field as a whole publishes results that replicate in a manner consistent with their expected power
to replicate; this seemingly argues against the possibility of systematic flaws in GWAS methodology.
The two significant predictors of aberrant replication performance, beyond the Winner’s Curse itself,
are (1) incorrectly reporting maximum sample size instead of per-variant sample sizes, reflecting
locus-specific missingness; and (2) conducting replication in samples of different continental ancestry
than those used in discovery. Corresponding to reporting error and linkage disequilibrium effects,
these influences are not surprising. Yet we have shown (Figure 2.5, Figure 2.6) that, within the
papers considered here, these factors are necessary and sufficient to explain all internal replication
discrepancies. This result is both novel and reassuring.
Though we present data separately for papers violating one of the two consistency conditions
(see Figure 2.9, Figure 2.10, Table 2.5), we do not present extensive analysis or conclusions for these
substrata. Unfortunately, the number of papers in each bin becomes quite small, in particular the
mere four papers with different ancestries in discovery and replication but correct per-locus sample
sizes. With such small counts, given the large paper-level heterogeneity we observe in Figure 2.2,
we hesitate to draw conclusions about these subsets. This prevents direct evaluation of the relative
importance of ancestry and sample size in replication prediction; in practice, it is likely variable,
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Figure 2.12: Chromosomal distribution of loci from 100 papers used in this study. In-
cludes all loci brought forward from discovery, not filtered for independence. Datapoint shapes
correspond to approximate continental ancestry: CEU=European, YRI=(sub-Saharan West Afri-
can, ASN=East Asian. Individual sites are stacked horizontally when the same variant is tested in
multiple contexts. Distribution of variants across chromosomes is nonrandom relative to distribution
of SNPs in reference datasets (p < 0.00001). Generated using the software at [42].
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Figure 2.13: Chromosomal distribution of replicating loci from 100 papers used in this
study. Subset of data from Figure 2.12; includes only loci passing study-specific Bonferroni-
corrected replication threshold. Generated using the software at [42].
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dependent on the rate of missingness in a given study and the relative divergence between the
ancestries considered.
Several strategies have been developed for accounting for the Winner’s Curse in reporting of sig-
nals. The use of multiple stage GWAS, in which samples are conceptually partitioned into (possibly
several) “discovery” and “replication” phases for internal replication, may be considered an attempt
at removing positive bias in effect estimates. The discovery samples are used to reduce the pool of
candidate SNPs from ∼106 to ∼101−103, at which point replication samples are used to verify that
the selected SNPs maintain their direction and approximate magnitude of effect in an independent
sample. Unfortunately, in many studies that make use of the discovery and replication partition,
the final reported results are not solely based on the replication sample. Most commonly citing the
argument in [43], studies frequently meta-analyze effect estimates from discovery and replication
for a given SNP. This joint estimate maintains the benefits of prioritization by discovery, namely
in reducing the cost of the study by minimizing the number of variants assayed in the replication
samples. However, this estimate incorporates the probabilistically biased estimate from discovery,
possibly attenuated by the less-biased estimate from replication. Thus while the argument of [43]
holds, stating that meta-analysis of two-stage studies maximizes power to detect variants, this in-
crease in power comes at the cost of both increased false positive rate and significant bias in the
estimate of effect at true, detected signals.
Our selection of the Winner’s Curse correction method of [18] is based on two considerations.
First, and most importantly, we lack access to the raw genotype data behind the loci we consider,
as is required in [20]. Moreover, the number of variants reported in each study is unpredictable:
in some cases there is just a single variant reported, whereas in others the investigators considered
several hundred. In the case of the former, we cannot reliably apply methods like [44], which
intrinsically require summary data from a large number of the most associated variants in a study
to generate an effect estimate distribution. Both of these limitations strongly call for a method such
as [18], in which correction is applied individually to each variant using only summary data. Yet
this remains a limitation of our study, as we are not practically able to evaluate alternate methods
of WC correction.
This study exclusively addresses the performance of internal replication in quantitative trait
GWAS. Yet other forms of replication are of just as much importance to the field. External repli-
cation, in which the results of one study are tested by independent investigators, is an important
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metric of the reliability of a field. In other contexts, external replication is known to perform at
much lower rates than internal replication, suggesting various forms of bias. There is furthermore
the consideration of functional replication, here broadly meaning the extent to which meaningful
biological insights can be derived from GWAS data. Both of these forms of replication are largely
unaddressed by the current study, nor indeed are they considered by the majority of GWAS publi-
cations; this does not diminish their importance. It is entirely possible that our results concerning
the correct performance of internal replication may coexist with extremely low rates of external
replication. Yet internal replication itself remains an important component of the field, and one in
need of proper characterization. This study emerged from a discussion of the performance of internal
replication in GWAS, when we discovered that there were no available data to prove one way or the
other whether the internal replication model was effective in practice. We hope that our analysis
provides one measure of reassurance about the fundamental reliability of the GWAS model.
Perhaps the most unusual observation of this analysis is the substantial proportion of manuscripts
in the field that do not provide enough information to actually allow independent validation of their
results. While some of the filters applied in our QC pipeline were present simply for ease of modeling,
at least 58% of papers we collected failed to include the minimal amount of reporting to fully prove
their claims of replication. This situation is a failure both in data reporting by authors and by
peer review in journals. Combined with variable definitions of replication, we suggest this accidental
lack of transparency substantially contributes to perceived unreliability of statistical genetics within
other scientific disciplines. A higher standard of reporting, that will not only enable computation of
unbiased effect estimates, but also list them explicitly, may be beneficial for the field.
The collection of these studies provides metrics other than simply replication rate. A primary
example is the tabulation of ancestries studied in each analyzed paper (Table 2.4). We observe, as ex-
pected, a significant overrepresentation of European ancestry samples across these studies (expected
13.3% based on global census data [37, 38], observed 88.1%). This is accompanied by a concomi-
tant underrepresentation in the other two major continental ancestries available, (East) Asian and
(Northwest) African; in particular, African ancestry samples represent a mere 0.51% of samples
analyzed in these papers, consisting of a Nigerian sample of approximately 1100 individuals, and a
study of several hundred Moroccan Arabs. Note that we are deliberately making vast simplifications
of minimally hundreds of distinct ancestry groups from all the countries of these continents, as this
is consistent with the approximations used in the field.
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I highlight these numbers in an attempt to provide metrics for what should be an apparent
characteristic of the field to anyone who has read the literature over the past decade: human genetics
is a field that studies whites. There are various explanations for these discrepancies in population
coverage, which are largely beyond the scope of this document. Yet without doubt, the bulk of
scientific knowledge about complex trait genetics is directly applicable to, maximally, 13% of the
global population. We should not shy away from this number or make excuses for it, but rather
directly contemplate the implications of this statistical and cultural bias for the coming years of
medical genetics. In particular, any impact of personalized medicine through individual genome
sequencing will be stratified first by existing racial bias in scientific genetics, and then furthermore
not just by the cost of the sequencing itself but also by the cost of the treatment suggested by the
sequencing. Existing race, gender, and class disparities in access and quality of medical care and
for-profit medical insurance coverage will intersect [45] with genomics sampling biases to further
restrict the utility of the scientific endeavor to a privileged elite.
We detect significant evidence for publication bias, the preferential publication of results based
on their perceived quality. In particular, as shown in Figure 2.2, journals of higher impact factor,
most notably Nature Genetics, published studies that replicated more variants than expected based
on their statistical power; the inverse relationship holds as well. While this may intuitively suggest
that the most robust results are published in the best journals, there is no intrinsic reason that the
results of a study that replicates according to its statistical power distribution should be less robust
than those of a study that replicates more often than should be possible. Rather, as is often the case
with publication bias in other contexts, we raise concerns that the competitive publication of GWAS
is giving rise to a publication record with invalid statistical properties, an important consideration
that is not widely appreciated at this time.
Somewhat surprising is the lack of a clear ranking bias, in which studies combine variants at
a locus according to strength of association, thus biasing each locus’s indicator SNP beyond the
standard Winner’s Curse. This process, which has been termed “LD clumping,” is reasonably
common, but was not consistently reported as used in the papers we analyzed. In some cases, papers
reported data for all variants at a locus, and we implemented our own version of LD clumping, by
randomly selecting a variant at each locus and discarding all other variants within a conservative
physical distance. This process may have somewhat attenuated any ranking bias in this dataset;
but it is quite likely that some of the fit deviation observed in our dataset is attributable to ranking
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bias, yet is simply not strong enough to create systematic significant deviation at the granularity of
the tests we apply here.
The indirect method of data collection used in this study raises several difficult questions con-
cerning data consistency. Due to the sheer volume of papers analyzed in the course of this study,
we must assume some errors are included within our data: both in the form of flawed data col-
lection on my part, and mistaken reporting from the individual papers that was missed in both
peer review and our manual inspection. Of particular note, for several tests included in this study,
we have assumed for our statistical models that these papers report complete sets of loci brought
to replication. We have furthermore specifically removed papers that transparently report partial
subsets of results. However, without access to raw SNP lists from the contributing GWAS, there
is no method to directly verify this criterion. There are also concerns about the low precision of
data typically reported in GWAS publications. While we are able to make bulk conclusions across
many loci, calculations at individual loci are somewhat unreliable. In particular, we have attempted
to recompute the apparent sample size per variant for studies that have reported maximum sample
size only; however, low precision data have made the resulting sample sizes rather unreliable, even
generating in many cases sample sizes larger than the original value. Future analyses of this kind
would strongly benefit from access to more of the raw data from contributing studies, should the
resources be available for such an undertaking.
It is important to note that the restriction of analysis to quantitative (normally distributed)
traits limits the direct conclusions we may draw to those same studies. This leaves the remainder of
GWAS, which typically study binary disease traits and make up approximately 67% of the NHGRI-
EBI GWAS Catalog. The methods used in [18] were initially developed for case/control studies and
operate on regression test statistics, meaning the approach we have taken here may be easily applied
to case/control studies in a later analysis. However, the practicalities of data collection meant that
it was not possible to more than double our data acquisition for this study. We see no particular
reason to assume different conclusions will be drawn based on binary trait studies, and suggest that
our conclusions may provide a reasonable starting point for the interested analyst.
This study is not designed to counter-productively single out individual papers or investigators.
For transparency, the full citation list is included (S1 File). I directly disclose my own statistics
among considered papers. I contributed to 12 papers (3.6%) in the initial pool, two passing QC
(consistent with expectation, Binomial given overall rejection rate across all papers, p = 0.7751).
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Seven of the ten removed papers provided incomplete data for replication, more than expected by
chance (Binomial given rate of this error across all papers, p = 0.007). This anecdotal observation
of papers focusing on anthropometric traits suggests the consistency of stylistic conventions within
a phenotypic field to translate into recurrent faults in data reporting.
2.6 Conclusion
The Winner’s Curse correction algorithm used here is based on a simple and fast method of ge-
nerating unbiased effect estimates [18]. Our implementation [46] requires simple input parameters
(replication threshold, SNP frequency, etc.) available from studies in the field with no paper-specific
modifications required. This tool models a traditional two-stage GWAS design, as opposed to a pa-
radigm of merging data from both study stages [43]. While strict staging is less powerful in detecting
true associations, meta-analyzing discovery and replication results in effect estimates still subject to
directional bias from discovery, and is thus not considered in our software.
This analysis provides the first systematic evidence that quantitative trait association studies
as a whole are replicable at expected rates. The fairly lenient quality control required to generate
such a result is instructive: papers conducting discovery and replication in populations of similar
ancestry and reporting accurate sample sizes replicate according to their predicted power. That
these criteria are met in only 12% of all successfully published papers indicates intrinsic flaws,
not in the paradigm of GWAS, but rather in study design and reporting standards. Correction of
discovery effects provides distinct advantages for any GWAS study. Most fundamentally, replication
at expected level is a sanity check for the analyst. Furthermore, WC-correction allows rational and
optimal prioritization of variants for replication. Finally, as a field, it is critical for GWAS to report
correct, rather than inflated results.
2.7 Methods
2.7.1 Notation
We consider M independent loci brought forward to replication from all papers combined. Each
individual paper x contributes Mx loci to this total. A variant has an estimate of effect βobs on a
given phenotype as well as a standard error of that estimate s, both computed from some form of
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linear regression. Significance, either for bringing variants forward from discovery, or for considering
variants successfully replicated, is defined based on a p-value threshold αx. The corresponding test
statistic βobss is standard normally distributed; φ, ψ are thus the PDF and CDF of the standard
normal distribution, respectively.
2.7.2 Data Collection
The NHGRI-EBI GWAS Catalog [2, 3] is an online resource that collects certain annotations for
all SNPs reported as significantly associated with a human trait. As significant association and
successful peer review are the only major criteria used for inclusion in this database, we used it as
a reasonably unbiased source of papers in the field across a variety of phenotypes and journals. We
restricted the articles selected from the database to fit our modeling requirements as follows. The
papers selected must primarily:
1. study at least one quantitative trait;
2. be published in a journal with a primary focus on human genetics;
3. provide for both discovery and replication:
 regression effect;
 regression standard error;
 allele frequency; and
 sample size
4. provide data for all variants brought forward to replication; and
5. model a minimally two-stage (discovery and replication) study design with a p-value threshold
used to select variants for replication.
The full list of filters and papers lost due to each criterion is shown in Table 2.3. Whenever
possible, we made reasonable accommodations to the papers to attempt to include them in this
study. We consider variants novelly discovered in each paper, as opposed to those previously reported
for a trait in question, as those are the variants typically brought forward for replication. Papers
conducting multiple GWAS (i.e., reporting multiple phenotypes tested in the same study sample)
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had all novel discovered variants from all traits included in the analysis, and are conservatively
reported as a single unit in this analysis. For studies that reported a single allele frequency per
variant, as opposed to a distinct frequency for each of discovery and replication stages, we used that
one frequency for both stage instead. Studies that did not report a variant-specific sample size, to
accommodate for differential missingness at different sites, were assigned the maximum available
sample size assuming no per-site missingness. These modifications will introduce noise into the final
analysis, yet a large percentage of papers required at least one of these modifications and thus were
permitted in the interest of representation and sufficient sample size.
Studies with different replication designs were compelled whenever possible into the traditional
two-stage format we use here. Thus for studies that attempted multiple non-tiered replications,
followed by a meta-analysis of all discovery and replication panels together, we conducted the re-
plication study meta-analysis manually using standard error weighting in METAL [47]. Studies
that conducted tiered replications were included with the first tier replication, in which all variants
passing a threshold from discovery were tested, used for their replication study.
2.7.3 Winner’s Curse Correction
To perform bias estimation, we use an implementation of the model in another study [18]. The
major benefit of this model is that it may be applied to variant summary statistics as opposed to
raw genetic data. As the non-parametric method BRsquared [20] requires raw genetic data, we did
not consider this alternative. The maximum likelihood model we use is as follows:





















Here, βobs is the (likely biased) effect estimate observed in discovery; βtrue is the conceptual
underlying unbiased effect of the variant in the source population; and c is the test statistic corre-
sponding to the discovery α threshold in a given study. The expected bias of the observed effect,
E[βobs − βtrue], scales inversely with the distance between the observed test statistic and the cutoff
applied to variants brought forward to replication. The bias can be solved using any standard zero-
finding algorithm (for example, Brent’s method as implemented in C [48]). Note that in situations
in which the observed test statistic far exceeds the α threshold, each component of the bias in the
above equation is dominated by one or the other of the paired terms; only when the statistic is close
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to the threshold (that is, when the expected bias is large) do both terms meaningfully contribute to
the bias estimate.
2.7.4 Independence of Loci
To simplify predictions of replication efficiency, we considered an independent subset of all reported
loci. As we lack direct access to the genetic samples used in these studies, we extracted a subset of
the variants such that no two variants in a paper are situated within one megabase of any other.
This is a very simple modification of the standard clumping protocol used in GWAS studies [49].
To prevent additional bias, we report a random variant from each locus, not necessarily the most
strongly associated in discovery. This will effectively guarantee that each variant represents a single
locus with only minimal linkage disequilibrium between variants, but is conservative in the sense
that it discards any secondary signals present among the replicated variants. Furthermore, this
approach may attenuate functional annotation burden testing if the strongest association in an LD
block is preferentially causal. While certain papers specifically address the possibility of secondary
signals by sequential conditional analysis of variants, the inconsistency of this analysis and absence
of it in many papers led us to seek a uniform treatment of all papers in this study.
2.7.5 Definition of Replication
The concept of “internal replication” may be interpreted differently in different reports. We consider
three definitions of replication for this study, to observe different characteristics of the data:
1. replication at nominal α = 0.05 [“nominal”]
2. replication at α = 0.05Mpaper [“Bonferroni”]
3. replication within deciles of variants [“deciles”]
We specifically only consider methods in which replication is determined from the replication
study alone. The nominal and Bonferroni methods are commonly used. We use the decile method
to investigate the behavior of the predicted power [50] to replicate according to the strength of an
association signal. We compute decile χ2 goodness of fit, using average power to replicate in each
bin across all variants. This permits a formal analysis of differential performance of replication at
different levels of replication stringency.
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Given a set of variants and their predicted power to replicate at a given α threshold, the number
of observed replications is distributed as Poisson binomial with success probabilities equal to each
individual variants’ power to replicate (see below). This is a generalization of a Binomial distribution
in which each Bernoulli trial is allowed to have a known but variable success rate. We use the
implementation of this distribution in R [51]. We further adapt the standard two-tailed Binomial
test for use with the Poisson binomial CDF implemented in this package.
We note that under certain assumptions the number of replications will asymptotically be distri-
buted normally. However, depending on the α considered, many variants analyzed here have power
of effectively, or within machine precision, 0 or 1; with our limited sample size, the convergence
properties of our dataset will be undesirable, and thus we use the exact distribution at the cost of
computational efficiency. This process may be considered a fitting of the model according to which
the WC-corrected discovery data correctly explain the observed replication data.
In several instances, we evaluate the effects of filtering certain subsets of papers based on various
criteria, and the extent to which this causes fit criteria to return to null expectation. As this
evaluation is potentially confounded by reduced statistical power, in all cases we test whether the
change in p-value is significantly different from expectation under random subsampling of variants
matched on total power to replicate amongst the observed variants.
2.7.6 Power to Replicate
Assuming the discovery and replication sample of a study are drawn from the same source population
with shared expected effect at each variant, the power to replicate a discovered variant v for a
quantitative trait under the additive model is
power(α,ncpv) = 1− χ21((χ21)−1(1− α),ncpv)
In brief, the power to detect a signal at an α threshold of p is the probability of the variant
exceeding the required test statistic from the null, but under the alternative distribution which is








trait variance− 2β2obsf(1− f)
where N is the replication sample size and f is the replication allele frequency of the variant. This
f should be the actual allele frequency in the replication sample; however, studies sometimes report
fhapmap from the closest reference ancestry as a means of protecting patient anonymity. Overall, the
predicted number of replications across all variants in a paper is the sum of the power to replicate,
as a function of predicted effect size and replication sample size and frequency, across all variants
analyzed.
2.7.7 Poisson Binomial Distribution
The standard binomial distribution represents the probability of observing k successes in n trials
with a fixed success probability p; in other words, the sum of n Bernoulli trials with a common
success probability. The Binomial probability density function is thus






The Poisson binomial distribution is the extension of the Binomial distribution to a series of
Bernoulli trials with arbitrary success probabilities at each trial. Thus the probability density of this
distribution is defined as follows. Consider each S of the n! permutations of the integers 1, 2, . . . , n.
Then the pdf is











In other words, in the place of the standard Binomial coefficient, one must iterate through all
possible sets of k integers on the sequence [1, n]. This probability is not closed and poses serious
computational issues; this study uses a publicly available implementation of the density function in
R[52, 51]. The standard two-tailed Binomial test in R was then manually modified to function with
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the Poisson binomial distribution.
2.7.8 Sample Ancestries
These papers demonstrate the coverage of population ancestries in the field of quantitative trait ge-
netics. We report and analyze the ancestral coverage of these studies using the simplifying summary
statistic of continent of ancestry (Europe, Africa, East Asia), tracing generally the ancestries of the
original HapMap2 populations. We include a fourth category for African American samples, the
largest admixed population nonnegligibly represented in the papers. This geographical partitioning
matches the ancestry assumptions used in GWAS methods such as genotype imputation.
Ancestry group counts are computed from maximum reported sample size per cohort per paper.
In studies where cohorts of different continental ancestry are meta-analyzed, sample sizes are appro-
priately partitioned to the contributing ancestries. No adjustment is applied for papers reporting
on the same cohort. For comparison to what the field’s sample sizes would be under random global
sampling, global population estimates are computed [37, 38].
2.7.9 Functional Annotation
We tested loci for nonrandom annotations. This test is usually conducted with access to the full set
of variants tested in an individual study. As in this study design such information is masked, we
restricted the analysis to papers using HapMap2 imputation in their discovery data; considered only
SNPs present in HapMap2; and restricted the data further to European ancestry discovery data,
which includes the majority of papers in the dataset.
We annotated all variants in the CEU subset of HapMap2 using ANNOVAR [53]. We computed
the average rate of functional annotations in the true set of variants. To generate a null distribution,
we matched true variants on allele frequency and, when appropriate, whether the variant was located




Probabilistic Genotype Data and
Improved Signal Detection with
Multiple Imputation
3.1 Abstract
Missing data are an unavoidable component of modern statistical genetics. Different array or sequen-
cing technologies cover different single nucleotide polymorphisms (SNPs), leading to a complicated
mosaic pattern of missingness where both individual genotypes and entire SNPs are sporadically
absent. Such missing data patterns cannot be ignored without introducing bias, yet cannot be infer-
red exclusively from nonmissing data. In genome-wide association studies, the accepted solution to
genotype missingness is to impute missing data using external reference haplotypes. The resulting
probabilistic genotypes may be analyzed in the place of genotype calls. A general-purpose paradigm,
called Multiple Imputation (MI), is known to model uncertainty in many contexts, yet it is not wi-
dely used in association studies. Here [54], we undertake a systematic evaluation of existing imputed
data analysis methods and MI. We characterize biases related to uncertainty in association studies,
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and find that bias is introduced both at the imputation level, when imputation algorithms generate
inconsistent genotype probabilities, and at the association level, when analysis methods inadequa-
tely model genotype uncertainty. We find that MI performs at least as well as existing methods or
in some cases much better, and provides a straightforward paradigm for adapting existing genotype
association methods to uncertain data.
3.2 Summary
Genetic research has been focused on analysis of datapoints that are assumed to be deterministically
known. However, the majority of current, high throughput data is only probabilistically known, and
proper methods for directly handing such uncertain genotypes are limited. Here, we build on existing
theory from the field of statistics to introduce a general framework for handling probabilistic genotype
data obtained through genotype imputation. This framework, called Multiple Imputation, matches
or improves upon existing methods for handling uncertainty in basic analysis of genetic association.
As opposed to such existing methods, our work furthermore extends to more advanced analysis,
such as mixed-effects models, with no additional complication. Importantly, it generates posterior
probabilities of association that are intrinsically weighted by the certainty of the underlying data,
a feature unmatched by other existing methods. Multiple Imputation is also fully compatible with
multi-cohort meta-analysis. Finally, our analysis of probabilistic genotype data brings into focus
the accuracy and unreliability of imputation’s estimated probabilities. Taken together, these results
substantially increase the utility of imputed genotypes in statistical genetics, and may have strong
implications for analysis of sequencing data moving forward.
3.3 Introduction
Genome-wide association studies (GWAS) have become a primary tool to elucidate the correlations
between SNP genotypes and complex phenotypes in large cohorts. Association studies initially
assumed the existence of genotype calls: for each sample at each assayed variant, either reference
allele homozygote, heterozygote, or alternate allele homozygote. As such, the methods developed
for analyzing GWAS also assumed the existence of such perfect-confidence genotype data. The
association study design and related analysis methods have remained in force even as the field
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has transitioned into the sequencing era and more complete data have become available. Yet in
all situations, due to technical and financial limitations, association studies only partially assay
the set of common variants in any organism. The variants included on a SNP array typically
only include a small fraction of the total pool of variants present, and even sequenced variants are
called incompletely and inconsistently. Furthermore, due to the low magnitude of effect of most
trait-associated variants, studies prioritize sample size via multisite meta-analysis, involving genetic
samples assayed on different technologies. This study design results in a complicated missingness
pattern across the entire conceptual set of common variants in a sample. Yet due to shared linkage
disequilibrium between different samples, this missingness can be overcome with the addition of
external reference data.
Genotype imputation probabilistically estimates unknown genotypes for a study sample by le-
veraging external reference haplotypes ascertained at a superset of SNPs [21]. Genotype calls and
genotype probabilities are fundamentally different. Genotype calls are considered certain data and,
under the traditional additive model, may be represented as an integer count of a reference allele
present for each study individual. Unfortunately, statistics developed for such a genotype model
cannot be directly extended to probabilistic data, as they are incapable of representing the variance
component introduced by uncertainty. This is critical to understanding the traditional challenge
in analyzing imputed genotype data: existing methods are not directly compatible with uncertain
data, so probabilistic genotypes must be projected to a lower-dimensional approximation resembling
genotypes, with a concomitant loss of information and introduction of bias.
Three primary methods have been developed for the handling of uncertain data in genetic asso-
ciation studies. For the first method, and at one extreme, probabilities may be converted to call-like
integral counts by choosing the genotype with the largest probability. This paradigm requires no
additional modification of the analysis method for genotype calls, but almost all meaningful infor-
mation about uncertainty is lost. For the second method, in some situations, genotype probabilities
may be converted into expected counts of the reference allele: the “allelic dosage.” This strategy
attempts to maintain some of the uncertainty of the genotype estimate by allowing non-integral
values: for example, when the heterozygote and reference allele homozygote classes are equiprobable
and the alternate allele homozygote has 0 probability, a sample is considered to have 1.5 alleles.
Unfortunately, this strategy is only useful when the underlying algorithm extends to nonintegral
data (for example, a generalized linear model with continuous predictor); furthermore, there is no
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rigorous proof of the degree of bias or information loss incurred using this method. Finally, as a
last method, the desired statistic may be modified to directly operate on probabilities [22]. This
option attempts to include all uncertainty information at the cost of additional work creating a new
algorithm. In practice, this type of custom algorithm design is limited to simple GLM methods;
other studies in the field creating more complex statistical models for association studies do not
undertake this additional work [55, 56, 57, 58, 59, 60].
In the statistics literature, Multiple Imputation (MI; distinct from genotype imputation; [23]) is
the rigorous method of conducting analysis on probabilistic estimates of uncertain data. The details
of MI are discussed in Methods. Briefly, a small number of complete datasets are randomly drawn
according to and consistent with the probability data. These datasets are then analyzed using any
standard analysis technique that asymptotically generates a normally-distributed effect estimate β
and standard error estimate s. Importantly, MI is not a method of estimating hidden data, but
rather a method of handling existing estimates. The performance of MI, and indeed of all imputed
data analysis methods, is reliant on the quality of the underlying genotype imputation. Imputation
accuracy, the agreement between predicted and true genotype, tends to vary across both imputation
“quality,” as estimated by most imputation software, and minor allele frequency. The extent of this
variable performance has not, to our knowledge, been rigorously assessed.
In this study, we seek to rigorously evaluate this variable genotype imputation performance. We
show a significant deviation between genotype probabilities generated by imputation, and empirical
probabilities estimated at the same sites. This failure of probability consistency is an important
confounding effect in imputed data analysis. We show that Multiple Imputation matches or improves
upon performance of existing imputed data analysis regimes by better prioritizing true positive
associations, while additionally being straightforwardly extensible to future analysis algorithms.
3.4 Results
3.4.1 Imputation Accuracy by Genotype, Frequency, and Quality
We compared the allelic dosage (Methods) to the “true” genotype count based on masked genotype
data. Figure 3.1 shows the fraction error between allelic dosage from imputation and masked ge-
notype, stratified by genotype class, allele frequency, and reported imputation quality metric (here-
after called “r2”). We observe that a single quality metric r2 masks significant deviations in mean
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Figure 3.1: Relationship between quality of estimated allelic dosage from IMPUTE2
imputation and predictors of imputation quality. Data are estimated from 10% of the original
chip (59808 SNPs) masked from imputation. Discordance of predicted allelic dosage (Y-axis) is the
fraction difference between dosage computed from imputation probabilities and dosage based on
masked genotype data: for example, if the true genotype is reference homozygote and the allelic
dosage from imputation is 1.4, the discordance is |2−1.4|2 = 0.3. Left panel: imputation quality
greater than 0.9; right panel: quality between 0.8 and 0.9. Clusters correspond to minor allele
frequencies of 10%; individual bars represent quality stratified by masked genotype. “Predicted”
bars correspond to expected concordance assuming independence of individual haplotypes. Error
bars represent 95% confidence intervals of mean discordance estimate.
quality between different genotype classes and different allele frequencies. For imputed SNPs re-
ported to be of high quality (r2 > 0.9, left panel; top 40% of GWAS-used SNPs, Figure 3.1 and
Figure 3.3), and with sufficiently high minor allele frequency, imputation is indeed well-behaved:
variants with minor allele frequency above 0.3 have less than 3% discordance with similar perfor-
mance across genotype classes. However, SNPs of lesser imputation quality (0.8 ≤ r2 ≤ 0.9, right
panel; approximately 18% of GWAS-used SNPs, Figure 3.1 and Figure 3.3) or low minor allele fre-
quency are inconsistently imputed. Minor allele homozygotes and heterozygotes in particular are
subject to highly inflated error rates. While differences across the SNP strata are observed with
both IMPUTE2 and minimac3 imputations, the magnitudes observed are distinct (Figure 3.2 and
Figure 3.4). Equivalent results are observed when evaluating performance by fraction of best-guess
genotypes from imputation not matching masked genotypes (Figure 3.5).
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Figure 3.2: Relationship between quality of estimated allelic dosage from minimac3 im-
putation and predictors of imputation quality. Data are estimated from 10% of the original
chip masked from imputation. Discordance of predicted allelic dosage (Y-axis) is the fraction diffe-
rence between dosage computed from imputation probabilities and dosage based on masked genotype
data: for example, if the true genotype is reference homozygote and the allelic dosage from impu-
tation is 1.4, the discordance is |2−1.4|2 = 0.3. Left panel: imputation quality greater than 0.9; right
panel: quality between 0.8 and 0.9. Clusters correspond to minor allele frequencies of 10%; indi-
vidual bars represent quality stratified by masked genotype. Error bars represent 95% confidence













Figure 3.3: Distribution of imputation quality from IMPUTE2 imputation. X-axis: IM-
PUTE2 info (quality) metric; Y-axis: proportion of full set of variants within this quality bin.












Figure 3.4: Distribution of imputation quality from minimac3 imputation. X-axis: mini-
mac3 r2 metric; Y-axis: proportion of full set of variants within this quality bin. Distribution is
left-truncated at common quality threshold. Final bin with quality greater than 1 indicates small
percentage of variants where empirical variance exceeds that of the expected binomial distribution.


































Figure 3.5: Relationship between quality of best guess genotypes from IMPUTE2 im-
putation and predictors of imputation quality. Data are estimated from 10% of the original
chip masked from imputation. Discordance of predicted genotypes (Y-axis) is the fraction of best
guess genotypes for a given bin that do not match the corresponding masked genotype. Left panel:
imputation quality greater than 0.9; right panel: quality between 0.8 and 0.9. Clusters correspond
to minor allele frequencies of 10%; individual bars represent quality stratified by masked genotype.
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Figure 3.6: Evaluation of the consistency of probability scores from IMPUTE2 impu-
tation. Data are estimated from 10% of the original chip (59808 SNPs) masked from imputation.
X-axis: 0.02-width bins of imputation probabilities; Y-axis: mean deviation between expected and
observed accuracy. Data series correspond to results stratified by genotype class. Left panel: IM-
PUTE2 info metric greater than 0.9; right panel: info metric between 0.8 and 0.9. Error bars
represent 95% confidence intervals around mean consistency estimate.
3.4.2 Imputation Probability Consistency
We next examined the imputation probabilities themselves, to evaluate whether probabilities ge-
nerated by imputation software correspond to the empirical probability of observing a genotype at
a particular site. Results for this comparison for IMPUTE2 probabilities are shown in Figure 3.6,
across strata of reported quality and predicted call probability. The empirical accuracy significantly
deviates from the predicted, and much more so with decreasing r2; Figure 3.7 shows similar plots
comparing the effect of decreasing minor allele frequency on this distortion, and show weaker but
significant changes with decreasing frequency. Of note, the heterozygote genotype class behaves in
a distinct but complementary fashion relative to the two homozygote classes.
These results are distinguishable between imputation programs: the effect is much stronger in the
IMPUTE2 imputation. The most substantial difference between the two programs is IMPUTE2’s
use of sequential imputation windows to improve performance through parallelization, with potential
accuracy tradeoffs, yet we have observed no differences caused by modifying this parameter. We note
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Figure 3.7: Evaluation of the consistency of probability scores from IMPUTE2 impu-
tation, stratified by allele frequency instead of imputation quality. Data are estimated
from 10% of the original chip (59808 SNPs) masked from imputation. X-axis: 0.02-width bins of
imputation probabilities; Y-axis: mean deviation between expected and observed accuracy. Data
series correspond to results stratified by genotype class. Left panel: minor allele frequency greater
than 0.4; right panel: minor allele frequency less than 0.1. Error bars represent 95% confidence
intervals around mean consistency estimate.
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and unpredictably (see, among many, [61, 62, 63, 64, 65]). Our observations are consistent with
intermittent observations of MACH-family algorithms nominally outperforming IMPUTE-family
algorithms in some cases, yet the precise reason(s) for these differences between similar software has
never, to our knowledge, been demonstrated.
3.4.3 Signal Enrichment with Multiple Imputation
We next sought to evaluate whether the ability to prioritize verified trait-associated SNPs in an
association study ranking was detectably different using MI or other existing algorithms. We con-
sidered 73 replicated loci from a large (N=339224 individuals) GWAS for BMI [66]. As expected
with our modest sample size of 2802, we have little power to detect the majority of these variants
at genome-wide significance α = 5 · 10−8. Nevertheless, if the variants are associated with the trait
at all, one expects the variants to be relatively better ranked in the final list of variants than va-
riants chosen at random from the study. We conducted a BMI genome-wide association study in
Health ABC, as discussed in Methods. Using these SNP association results, we computed the rank
percentile of each published variant, comparing these results for two existing imputed data analysis
algorithms and MI.
We evaluated the area under the receiver operating characteristic curves for PLINK dosage (for
allelic dosage), SNPTEST score (for parametric use of full probabilities}, and MI (Figure 3.8). MI
significantly outperforms all other methods (one-tailed DeLong test p < 2 · 10−16). We repeat this
analysis with a height GWAS in NFBC66 (Methods), and find a similar significant improvement
in signal detection by MI compared to other methods (one-tailed DeLong test p < 0.000376). We
conclude from this analysis that significant information loss may occur when uncertainty is incom-
pletely handled in imputed data analysis. There is no evidence in this comparison that Multiple
Imputation is ever inferior to other methods.
3.4.4 MI Changes the Null Distribution of Variants
Improved signal detection by MI may be attributed to several causes. In observing the additional
variance component in the multiple imputation model, sˆ2B (see Methods), we note that variability in-
troduced by genotypic uncertainty should result in decreased rankings for variants regardless of trait
























Figure 3.8: Receiver operating characteristic curves for Health ABC BMI association
with IMPUTE2 imputation. True positive associations are 73 established BMI variants from
[66]. Tracks correspond to uncertainty handling methods: allelic dosage (“Dosage”), score test
(“SNPTEST”), MI on imputed probabilities. Statistics on thresholded genotypes are not included
due to poor performance similar to that of “Dosage.”
rent association tests may lead to different expected distributions of variants in a ranked association
study across the quality spectrum, whether variants are trait-associated or not.
We sought to evaluate the null distribution of variant ranks across imputation quality. We calcu-
lated the percentile rank of each variant in the Health ABC BMI GWAS and sorted the variants into
bins across imputation quality. Results from this investigation are shown in Figure 3.9. All tested
methods have a statistically significant correlation between imputation quality and average rank (all
Pearson correlation test p < 2 · 10−16; comparable results for nonparametric tests). PLINK and
SNPTEST have indistinguishable magnitudes of effect (shared effect size −0.017, indistinguishable
with p = 0.44). Multiple Imputation shows a significantly stronger correlation than the other tests
(effect size –0.351, greater than other tests with p = 3.4 · 10−7). MI produces test statistics that
much more significantly incorporate uncertainty, through in particular the between-draw variance
component.
Published trait-associated variants tend to impute with higher quality than random variants from
a dataset due to selection bias, leading to the possibility that this global incorporation of quality by





























Figure 3.9: Evaluation of the null distribution of variants across an association study
ranking. X-axis: variant imputation quality bin; Y-axis: absolute deviation from uniform random
expected rank across all variants at given quality (that is, 50%). Data tracks correspond to PLINK
dosage analysis, SNPTEST exact testing, and MI.
unrelated differences between published variants and the global SNP distribution, we computed
empirical matched null sets for every published variant by drawing 1000 SNPs matched to this
variant with parameters r2 ± 0.01 and frequency ±0.01 of the true variant. Here we are drawing
variants from the association study itself; this null allows us to detect effects specifically on the
significant tail of the distribution over the bulk of variants. For most traits, these variants will
overwhelmingly be unassociated with the outcome, and thus this null will correspond to a true null
of no genetic association; in the case that this condition is untrue, this null will lead to relatively
conservative assumptions about the added performance of MI. We then regenerated ROC curves
for each analysis, this time controlling for the null rank of SNPs matched to the published variant
list based on these parameters. These results approximately correspond to trait-specific enrichment
effects caused by the various analysis methods. We find that adjustment for trait-secular shifts in
variant quality affects BMI and height differently. For BMI, MI continues to outperform PLINK
and SNPTEST (one-tailed DeLong p < 1.177 · 10−10). For height, null adjustment reverses the
previously-observed trends, such that MI tends to underperform PLINK and SNPTEST (one-tailed
DeLong p < 0.0025). We note that for this trait in particular, the null derived from drawing from
the association study itself may be conservative given the broad genetic basis for human height [67].
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3.4.5 Extensibility
To underscore the benefits of MI not simply on regression with existing uncertainty handling met-
hods, but additionally on more complex algorithms more difficult to directly adapt for use with pro-
babilities, we applied MI to EMMAX [56], a commonly used linear mixed model software package.
We ran EMMAX on both the Health ABC BMI GWAS and the NFBC66 height GWAS, with default
parameter settings and the IBS-based kinship matrices. We compared EMMAX with thresholded
genotype data and MI on imputed probabilities. The published version of EMMAX only accepts
integral count genotypes, thus no other comparisons were included in this test.
We detect significant improvement in relative percentile increase for BMI-associated variants that
is abrograted by null adjustment (one-sided DeLong test p = 6.663 · 10−12 and p = 0.09933 respecti-
vely). We find weak evidence for improved overall efficiency for known height variants (one-sided
DeLong test p = 0.01994), which under null adjustment becomes a significant underperformance of
MI relative to rounded genotype control (one-sided DeLong test p = 2.242 · 10−7); again, we note
that this null may be overly conservative in this trait context [67]. Evaluation of the null distribution
of variants for this experiment, analogous to the analysis in Figure 3.9, shows that the MI-mediated
rank shift is much smaller across both the frequency and variant quality spectrum. We propose that
the error model used in EMMAX is partially compensating for the additional uncertainty variance
component redundantly modeled by MI.
3.5 Discussion
In this study, we analyze the application of Multiple Imputation in the particular context of ge-
notype imputation. We find that existing analysis methods tend to increase noise in association
testing by incompletely modeling the uncertainty of genotype estimates across the entire set of im-
puted variants. This results not just in lower quality variants, for which information is limited,
receiving inappropriately high ranking; but also variants for which underpowered but significant
trait association is present becoming lost in statistical noise introduced by imputation. We furt-
hermore detect imputation program-specific inconsistencies in posterior genotype probabilities that
differently affect the three genotype classes. Overall, we characterize the complexity of imputation
probabilities and show that MI can improve association testing with uncertain data at the cost of
increased post-imputation computational time.
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This study particularly elaborates on the interpretation of a p-value from a probabilistic associ-
ation study. Based on the results in Figure 3.9, we see that existing analysis tends to rank variants
uniformly across r2: the p-value weakly incorporates imputation quality, enough so that the tests
are not correctly calibrated but insufficiently so to actually correct for differential uncertainty. This
poor calibration is verifiable with a true null: observing the null distribution of variants in our study
regressed against random standard normal traits, we observe a comparable correlation between va-
riant imputation quality and SNP ranking for SNPTEST (p = 0.001953). Dosage analysis does
not, in that context, recapitulate the correlation effect observed in our data, suggesting that the
trend is specific to our trait-associated null. This poor calibration is potentially shared by many
analysis methods in the field: following the simulation work of [68], we have found low magnitude
but significant anticonservative miscalibration when operating on probabilistic genetic data and
null traits for linear regression and a Kruskal-Wallis test on best-guess variants; dosage analysis;
and their generalized Kruskal-Wallis test that directly handles uncertainty (all Wilcoxon rank sum
p < 2 · 10−16). There is also a significant correlation between uncertainty for the Kruskal-Wallis
based tests in this simulation context (ANOVA p < 2 · 10−16). Association p-values are intrinsically
affected by genotype uncertainty, altering the expected null distribution from uniform random, but
this is simply an uncharacterized bias introduced by incompletely handling uncertainty, not a formal
characteristic with proven properties.
We suggest that this behavior is undesirable: if a SNP estimate is uncertain, then the behavior of
an ideal inference should be to proportionally downweight the ranking of that SNP in that particular
study in a predictable fashion. With Multiple Imputation, this uncertainty-induced variability is
correctly apportioned to the between-draw variance component sˆ2B , resulting in unmodified effect
estimates that are still suitable for cross-cohort meta-analysis. In the case of our example BMI
association study, the positive control variants used were all imputed with high confidence, yet MI
still showed a trait-specific rank improvement in these SNPs, due to the selective downranking of low
confidence variants with no or lesser phenotype association. In short, we see little reason to continue
using dosage or score test methods for handling imputation probabilities, when a straightforward
alternative with superior statistical properties exists.
The results in Figure 3.1 and Figure 3.6 broadly characterize imputation performance across
variant quality, frequency, and genotype class. Although parts of these results are hinted at in various
imputation papers (in particular, [69], but also [22, 70, 71, 63]), we have not before encountered a
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presentation of the severity of quality degradation across the full spectrum of frequencies. We urge
analysts in all contexts to avoid genotype thresholding, in particular using IMPUTE2 probabilities:
with decreasing frequency and quality, the likelihood of rounding to an incorrect genotype grows
extremely high. We also observe strong per-genotype class differences in performance, most severly
affecting heterozygotes. This is not a surprising result, given the integral nature of computational
prephasing in genotype imputation. In the modern genotype imputation protocol, prephasing is
a one-time burdensome computation that is not repeated, whereas the imputation step itself is
comparatively rapid and repeated many times as new reference panels become available. A useful
future analysis would investigate the specific impact of differential phasing quality on imputation
probability bias, and our results emphasize that prephasing should be reconducted as advancements
in the field yield higher quality phasing solutions.
We have observed in the literature a tendency to ignore uncertainty in genotype data when de-
veloping new algorithms. This elision is understandable in the sense that complete-case analysis is
typically substantially more straightforward to implement, and as a first approximation, uncertain
data may be converted seemingly straightforwardly to genotype “calls” via techniques such as roun-
ding. Yet in the case study of simple regression, we see that this approximation bears with it a cost
in loss of statistical power to detect trait-associated variants. One of the great benefits of MI is its
simple application to complete-case analytical tools, as each round of MI generates complete case
data. In the case of standard regression, this is a straightforward benefit; in the case of a method
such as EMMAX, one must balance the desirable avoidance of rounded probabilities with potential
complications of the standard MI variance component model.
One of the strongest justifications for the widespread use of imputation is the facilitation of
multisite multicohort meta-analysis, in which summary statistics from separate association studies
are combined to increase statistical power. The benefits of integrating imputation quality into
inference are magnified in this context. Under the current regime, either {β, s2} or {N, p} pairs
are the exclusive data provided to meta-analysis tools [47], leading to a downstream analysis that
treats different estimates of variants with different imputation qualities as estimates identical to one
another in expectation ascertained with perfect confidence. With nested model multiple imputation
([72], Methods), the improved model described in this study may be extended to meta-analysis.
A nested model MI meta-analysis will explicitly compensate for variable imputation quality across
contributing studies with inflated variance components corresponding to noise in the mean effect
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estimate or inflated standard error (i.e., imprecision in effect estimate introduced either by variable
imputation quality, fluctuations in allele frequency, or differential effect due to LD changes in different
studies). The cost of this extended meta-analysis regime is limited. In addition to the standard
{β, s2} pairs currently used to combine analysis, the within- and between-draw variance components
must also be submitted. These data require additional disk space but are relatively trivial to provide.
Crucially, the summary statistics from each individual draw are not required for this meta-analysis,
such that the growth in memory requirements for meta-analysis does not scale with the number of
draws conducted.
We note that by explicitly handling variable imputation quality in different studies, this meta-
analysis regime introduces potential sources of heterogeneity in the final meta-analysis result. Studies
with aberrantly high uncertainty may strongly influence the resulting meta-analyzed association
statistic. Note that this source of heterogeneity already exists, but is not rigorously modeled and
currently must be addressed by ad hoc filtering and quality control. We propose that heterogeneity
from differential imputation quality may be quantified by a heterogeneity test analogous to the effect
estimate heterogeneity I2 metric in METAL [47]. This test would quantify heterogeneity specifically
in the between-test variance component sˆ2B from contributing studies, which captures the noise
between individual MI draws introduced by meaningfully uncertain data. This test would enable
standardized detection of cases in which low imputation quality may require custom secondary
genotyping for validation.
In the statistics literature, starting with [23] and moving forward, the recommended number of MI
draws has varied widely. The original recommendation was that oftentimes 3–5 draws were sufficient
to retain most of the accuracy while minimizing computational burden. More recent publications (i.e.
[73]) have suggested that the original estimates of draws were insufficiently stringent. In this study,
we have used an a priori setting of 10 draws after testing various draw numbers’ effects on quality of
MI output, and balancing this impact with the added burden of multiple additional MI rounds. We
find that this draw count surpasses the point at which MI effect estimates tend to converge (Figure
3.10), but may in the case of particularly poorly imputed variants lead to suboptimal estimates of
between-draw variance (Figure 3.11). A useful target for future work would be the integration of
dynamic computation of the number of draws for convergence for individual variants, which in this
study is complicated by the manner in which our software interfaces externally with, rather than

































Figure 3.10: Evaluation of the effect of Multiple Imputation draw count on estimated
regression coefficients. X-axis: number of MI draws; Y-axis: observed Pearson correlation coeffi-
cient between regression coefficient estimates from masked data and estimates from MI on imputed
estimates over masked sites. Horizontal line corresponds to correlation between masked data and






































Figure 3.11: Evaluation of the effect of Multiple Imputation draw count on estimated
between-test variance component. X-axis: number of MI draws; Y-axis: absolute change in
between-draw variance component from one MI round to the next. Note this is a traditional boxplot
but the boxes are tightly clustered around y=0, leading to the boxes rendering as the small thick
back lines for each x value at y=0. The emphasis of these results is on the distribution of outliers,
corresponding to low-quality imputed variants with trait-correlated uncertainty.
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The existence of software-specific differences in the consistency of imputation probabilities is an
intriguing result that raises meaningful questions for the field. Though each program has its own
algorithmic features and drawbacks, the practical choice between imputation software often reduces
to the banal: ease of use, runtime and memory requirements. These features are important for
imputation study designs that may take weeks to months to complete. Yet here we show a more
substantive trend of probability bias that follows a distribution specific to particular programs. The
precise cause of these distortions is not clear. Further investigation may be warranted to determine a
method of adjusting the native probabilities generated from imputation using empirical distributions
based on masked comparison data.
We interpret the potential performance improvement of MI over other methods as a call to
reevaluate the use of thresholded genotype calls in other contexts. In particular, as the field continues
transitioning to sequence-derived variant data, the impact of thresholded certainty in sequencing
data analysis cannot be overlooked. We note that standard methods for rare variant analysis,
including burden testing, adapt to the high uncertainty in low frequency variant calls by using strict
quality control and relying on bulk information to resist the noise introduced by false positives. Yet
interpreting the probabilistic output of sequencing technology as a mechanism for completing data
in a NMAR setting (Methods), Multiple Imputation straightforwardly provides a consistent solution
for even complex statistical analyses.
In the case of statistical tests that analyze linked variants together, per-site marginal information
is no longer sufficient, as each MI draw must be taken from the joint distribution of all tested
sites. Yet with sequencing read data, this kind of analysis is not impossible: joint information can
be directly estimated from shared reads, creating a computationally challenging and yet feasible
method of rigorously handling genetic uncertainty without even linkage assumptions. The creation
of a standard module for interfacing with sequencing read data and dynamically generating such
joint probability information would be a significant contribution to the field.
Similarly, the draws conducted in multiple imputation implicitly assume independence of samples.
In the case of pedigrees or cryptic relatedness of samples, the sampling problem becomes much more
challenging. The imputation software analyzed in this study (IMPUTE2, minimac3) is designed to
handle unrelated population-based samples. The marginal probabilities generated by the algorithms
are not reflective of explicit joint distribution between related samples and thus are not directly
compatible with correlated genotype draws without additional modeling. One could synthesize
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probabilities that scale with both the imputed probabilities and the Mendelian transmission rules,
for example
P (child|data,parents) = P (child|data)P (child|parents)∑2
i=0 P (child = i|data)P (child = i|parents)
Unfortunately, such an approximation of the joint distribution would not be equivalent to ac-
tually modeling the combined structure of the data in the imputation software itself: for example,
when the parents and children are modeled separately, certain genotypes will be given nonzero pro-
babilities that would be rendered impossible by Mendelian transmission. In the case of BEAGLE
[62], duos and trios are specially handled according to externally specified pedigrees. The resulting
genotype probabilities then are reasonably considered to be conditional probabilities: for example
P (child|data,parents). In this case, the appropriate probabilistic relationships should hold: for
example,
P (child = aa) =
[
P (mother = aa) +





P (father = aa) +
P (father = Aa)
2
]
and thus consistent drawing could be conducted in a trio by first drawing the child, then drawing
the parent probabilities conditional on the result of the child’s draw. Ultimately, the suitability of
MI to a given application is restricted to situations where the probability-generating method is itself
appropriately suited.
Recent work ([74, 75, 76]) has produced algorithms (MIX, DISTMIX, ImpG-Summary) capable
of imputing association statistics from summary data, without the need for individual-level genotype
information. These methods offer substantial time savings relative to genotype imputation, at the
cost of reduced overall quality of estimates relative to existing HMM methods. The imputed test
statistic at a particular site is the mean of a multidimensional Gaussian distribution based on
neighboring test statistics and linkage disequilibrium data: this intuitively corresponds to an MLE
dosage estimate from genotype imputation probabilities. It is likely the method thus suffers from
analogous disadvantages to those of incomplete uncertainty handling in genotype imputation. One
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could imagine replacing a single mean imputed test statistic with instead a set of random variates
drawn from the underlying Gaussian; these draws would act as drawn genotypes in the analysis
in this study. Although multiple test statistics per variant would prove less useful for analysts
of individual studies, they would be more completely reflective of the uncertain nature of these
estimates. Furthermore, using sample size weighting, one could generate an MI regime in multi-
cohort meta-analysis in, for example, METAL [47], in which each set of drawn test statistics is used
to generate a separate meta-analysis dataset, and the resulting sets are combined using MI. Such a
regime would require further investigation, and most likely would require a substantial number of
iterations if many contributing cohorts used uncertain input data.
3.6 Conclusion
We characterize the behavior of modern genotype imputation tools in the context of GWAS, with
a particular emphasis on the interaction of allele frequency and genotype class. We find systematic
biases in imputation results, both in terms of concordance between estimated genotypes and masked
data, and between genotype probabilities and their corresponding rates. There remains substantial
room for improvement in genotype imputation tools, as these biases may manifest as unpredictable
association errors in downstream analysis.
The use of MI is not completely foreign to the field of statistical genetics. We note, however, that
its use is very limited, and has not been extensively compared to other, prevalent methods of handling
genotype probabilities. We evaluate MI in comparison to existing methods and show MI performance
is typically comparable to existing methods, and in certain contexts significantly outperforms other
existing algorithms. Furthermore, we emphasize the ease with which MI is extended to, conceptually,
all existing and future genotype call analysis methods with little additional effort. We foresee MI as
a simple and effective component of all probabilistic genotype analysis.
3.7 Methods
3.7.1 Study Datasets
For this project, we applied for access to and downloaded two SNP array and phenotype datasets
from the Database of Genotypes and Phenotypes (dbGaP) [77]. The Whole Genome Association
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Study of Visceral Adiposity in the Health Aging and Body Composition (Health ABC) Study, dbGaP
accession phs000169.v1.p1, contains 2802 individuals genotyped on the Illumina Human1M-Duo SNP
array. STAMPEED: Northern Finland Birth Cohort 1966 (NFBC1966), phs000276.v2.p1, contains
5415 individuals assayed on the Illumina HumanCNV370 array. Both datasets were requested and
approved under project 7955; they are available from the dedicated General Research Use collection
and do not require IRB approval.
The phenotype data released under this collection are quite limited. For this study we limited
analysis to simple anthropometric traits. For Health ABC, we conducted a BMI association study
with BMI (µ = 27.4, σ = 4.77) determined by age (µ = 73.6, σ = 2.87) and sex (51.2% female).
For NFBC66, we conducted a height association study with height in centimeters stratified by sex
(µW = 153.2, σW = 68.9;µM = 286.1, σM = 66.4; 52% female); age was not included for this
single-year birth cohort.
3.7.2 Sample Quality Control
Datasets on dbGaP have already been subjected to a round of cleaning by their depositors. Ne-
vertheless, for thoroughness we cleaned the SNP array data using a standard QC protocol. Briefly,
variants with minor allele frequency less than 1%, Hardy-Weinberg Equilibrium p-value and either
per-individual or per-SNP missingness greater than 5% were removed. Cryptic relatedness was esti-
mated using genome-wide IBS estimation in PLINK [49]. A large cluster of approximate first-cousins
was detected (IBS pˆi ≈ 0.125). For the purposes of this analysis, whether this is indicative of un-
reported pedigree structure or technical artifacts in genotype collection is irrelevant, as we are not
undertaking novel variant discovery, rather conducting comparisons relative to control data.
The remaining SNPs were pruned to an independent subset of SNPs using PLINK --indep with
default parameters, and these variants along with the maximal independent subset of individuals
were used for unrooted principal component analysis in EIGENSOFT [58]. Standard population
stratification along geographical axes is observed, confounding novel variant discovery but not ef-
fecting within-sample comparisons.
To prepare for genotype imputation, SNPs with complementary variant alleles were removed from
the dataset, and positions and SNP rsIDs were updated to those of the 1000 Genomes reference panel
we used (see below). Complementary allele variants are challenging to reconcile with datasets of
potentially different strand alignments. This is true when handling external datasets subject to
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unknown prior manipulation, but in particular in the case of modern Illumina arrays, which are only
annotated with “TOP/BOT” annotations instead of reference strand calls.
3.7.3 Prephasing and Genotype Imputation
Following modern genotype imputation guidelines [63], we first prephased our data using SHAPEITv2
[78] with the recommended parameters. Phased haplotype data were then probabilistically imputed
to the Version 3 1000 Genomes Phase 1 Integrated global reference haplotypes [79] using IMPUTE2
[70]. For comparison purposes, to establish whether effects observed were specific to the software in
use, in parallel we phased the genotype data using MACH [69] and imputed the resulting phased
haplotypes to the same reference panel using minimac3 [71]. Using the global reference data, a large
proportion of the approximately 40 million variants in the reference dataset are expected to not
segregate in the study samples and impute very poorly; thus, before downstream analysis, variants
with program-specific quality metric less than 0.4 were removed entirely. No per-genotype filtering
was conducted, to avoid reintroducing NMAR bias (see below).
3.7.4 Standard Analysis Methods
For standard association models under generalized linear models (in this case linear regression),
various methods currently exist for analyzing probabilistic genotypes. We selected two widely-used
methods of analysis for the purposes of this study. The genetics software PLINK, as of version 1.07,
has an “allelic dosage” method of genotype imputation, in which the additive predictor
dosage = 2P (aa) + P (Aa)
is included in a generalized linear model (note that this value is not equivalent to a perfect confidence
genotype, as it is permitted to be a decimal number between 0 and 2). This method projects the
two parameter posterior probability into a single dimension, thus losing information in many cases:
for example, this would consider the posterior probabilities {0, 1, 0} and { 13 , 13 , 13} to be equivalent.
The IMPUTE2 software used for imputation in this study has an accompanying analysis software
package, called SNPTEST [22]. This software comes with a custom score test for explicitly handing
genotype probabilities from imputation. The software has changed substantially since initial release;
the best documentation available for the probability-handling methods is at https://mathgen.
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stats.ox.ac.uk/genetics_software/snptest/snptest.v2.pdf. For this investigation, we solely
use SNPTEST’s frequentist methods, which can explicitly handle uncertainty.
3.7.5 Statistical Missingness Theory
Genotype imputation is a discipline-specific solution to a general statistical problem called “informa-
tive missingness” [23]. Consider a conceptual data matrix Y containing all phenotype and covariate
data for a study. Classical statistical analysis assumes Y is complete, containing no null entries, and
that all entries are known with perfect confidence. Study designs with null entries can be compel-
led into this format by removing all null datapoints before statistics are performed, resulting in a
so-called “complete-case analysis.”
The effect of deviations from these assumptions vary depending on the characteristics of the
missingness itself. Now assume that Y is the conceptual matrix containing all true datapoints with
perfect confidence. Missingness observed in realistic studies is encapsulated by a second matrix, M ,
where each entry Mij is 1 if Yij is missing in the true study, and 0 otherwise.
Using this framework, missingness can be partitioned into three general classes. If the distribution
ofM is independent of Y , the missingness is called “missing completely at random” (MCAR). In this
situation, corresponding to the classical model, all missingness can be safely ignored in downstream
analysis, with a potential loss in statistical power but no introduction of bias.
If instead the distribution of M is dependent on the data matrix Y , missingness can be clas-
sified in two separate cases. If the dependency can be reduced to simply the observed subset of
Yobs, where Y = Yobs ∪ Ymis, then the missingness is, somewhat misleadingly, termed “missing at
random” (MAR). Data that are MAR cannot be ignored while safely avoiding the introduction of
bias. However, due to the exclusive dependency on Yobs, the missing values can be probabilistically
imputed from Yobs and added into downstream statistical analysis.
In the worst case, the distribution of M is irreducibly dependent on Y ; such missingness is
called “not missing at random” (NMAR). NMAR data cannot be removed without potentially
introducing bias, and furthermore cannot be predicted solely from the observed data Yobs. The case
of genetic data collection is invariably NMAR, as missingness created by collection technologies such
as SNP arrays and sequencers exhibit different performance at different underlying genotypes, and
the selection of variants for SNP arrays is itself biased by numerous factors including but not limited
to predominant ancestry in early variation projects such as HapMap, variant location in the genome
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and neighboring sequence content, and allele class at the site of interest.
Genotype imputation is an attempt to project the NMAR missingness of genetic data collection
into an MAR condition. Due to linkage disequilibrium (LD), the nonrandom segregation of neig-
hboring variants over a limited number of generations, one can add externally collected, ancestrally
related haplotypes to the data (the Y matrix). The resulting partition of this matrix Yobs now ide-
ally contains sufficient information to probabilistically estimate missing genotype data in the original
dataset at both typed and untyped variants.
3.7.6 Multiple Imputation
The framework for Multiple Imputation is established in [23]. Briefly, the method assumes that
missing datapoints have been probabilistically estimated using some external method. From these
probabilities, an arbitrary d complete datasets are drawn from the specified probability distributi-
ons. In the case of standard single-variant analysis, conducting these draws is straightforward as
linkage disequilibrium can be ignored: thus for each sample at each SNP, the genotype is drawn
independently of all others.
Each draw is independently subjected to the desired statistical test. This results in d sets of
{βi, sˆ2i } effect and standard error at each variant. The Multiple Imputation consensus test statistic






























Here, βˆMI is the consensus effect estimate; sˆ
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W is the within-draw sample variance; sˆ
2
B is the
between-draw sample variance; and sˆ2MI is the total sample variance. The test statistic is the
ratio of the test statistic and sample standard error, βˆMI√
sˆ2MI







degrees of freedom. The resulting probability may be interpreted as a posterior
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probability incorporating both the evidence for association in the study and the actual reliability of
the genetic data.
Software implementing this Multiple Imputation regime (in beta) may be found at https://
github.com/cpalmer718/statgen-mi. This package features modularized, extensible interfacing
with existing analysis software, and bsub/qsub integration. In total, this implementation of MI
requires d times as long to run, and d times as much disk space, as a single analysis run, though
running in tranches per chromosome on a cluster can reduce the maximum memory and effective
time use by removal of intermediate files and quasiparallelization.
3.7.7 Meta-Analysis of Multiple Imputation
With Multiple Imputation, a simple regime for seamlessly correcting for different proportions of
uncertainty in the contributing analyses is available. Extending the logic used when combining d




























The new variance component sˆ2meta is the between-site variance of estimated test statistics. As-
suming a balanced study design in which each site runs the same number of MI rounds, the total
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. In the case of imbalances in the number of draws conducted in each contri-
buting cohort, more complex expressions might be derived, or alternatively a conservative estimate
of min(dm) may be used for the weighting factor in the total variance and degrees of freedom.
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Chapter 4




Missing genetic heritability in complex human traits may be explained in part by rare variation
[5]. Genome-wide association studies are not suited for analysis of such variants, as their primary
benefit is cost savings through the assay of a predetermined set of common SNPs. Rare variants
undetectable in large outbred populations may increase in frequency when captured in bottleneck
populations [80], potentially reducing the number of samples required to detect a signal. We thus
consider novel variation underlying risk of schizophrenia within a retrospectively ascertained sample
of Ashkenazi Jews. Previous work has shown a significant enrichment of novel putatively-functional
variants within Alzheimer’s patients in a study population of similar ancestry [31], as well as within a
large population-based schizophrenia cohort of different ancestry [10]. We find no such enrichment in
our study. There is strong evidence that the inclusion of relateds and duplicates leads to an inflated
novel variant call rate when sites that would otherwise be singletons are presented as doubletons
in the study. We further note nonrandom patterns of call rate and variant quality within the
samples of this study, primarily affecting the unmatched controls. There is evidence suggesting
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compromised selection and randomization of cases and controls during study design, leading to
systematic differences between case and control sequencing due in large part to stratified identity by
descent (IBD) between groups. These observations provide substantial support for stringent study
design and randomization when evaluating novel variant burden.
4.2 Summary
The sequencing era has substantially shifted the focus of human genomics from common variation to
rare and novel variation as possible contributors to trait variation. The detection of rare variation is
complicated by high false positive rates and low counts of rare alleles, making standard association
paradigms insufficient. To enrich a sample for interesting rare variation, we conduct a novel variant
burden analysis in schizophrenia cases of Ashkenazi Jewish descent, whose bottlenecked ancestry is
likely to increase the prevalence of high-impact variation. We find, in contrast to other studies of
comparable size, substantial sequencing artifacts that preferentially affect novel variation, rendering
standard “burden of rare allele” analysis unusable. Most notably, we have characterized the impact of
including distantly-related samples in a sequencing study, which if not properly randomized at sample
collection will create artifactual patterns of variant discovery that are correlated with phenotype.
In sum, though we find little of biological interest, this study provides insight into the technical and
study design concerns of novel variant testing that may be informative for future studies.
4.3 Introduction
Modern statistical genetics considers the genetic underpinnings of complex heritable traits, including
both quantitative traits with continuous measurement (such as height [8], body mass index [66],
blood marker levels [81], etc.), as well as binary traits with no apparent Mendelian basis (such as type
II diabetes [82], Alzheimer’s disease [83], asthma [84], and many others). The traditional model for
complex trait genetics involves the Common Disease/Common Variant (CD/CV) hypothesis [1], in
which variants of high population frequency (typically greater than 1% or 5% minor allele frequency)
contribute the majority of genetic heritability in traits exhibiting non-Mendelian behaviors. Borne
out of both biological and practical justifications, CD/CV has found significant empirical support
through hundreds of association studies ([85]; also Chapter 2 of this document).
68
Yet to many, the primary conclusion of the GWAS era is the incomplete picture of heritability
presented by CD/CV: for most traits, detectable common variants do not explain the entirety of
expected genetic effect, leading to the so-called “Missing Heritability” problem [12]. The selective
restriction of common variation to small contributions to trait variance is coupled with the possi-
bility of much larger magnitudes of effect in rare variation. In the most extreme case, individual
susceptibility to a trait or disease may be concentrated in personal novel mutations of large effect,
substantially complicating the process of describing the genetic underpinnings of heritable traits
across an entire population.
Schizophrenia is a serious psychiatric disorder with a putative genetic basis. Likely causal variants
have been detected in both the common [86] and rare [10] frequency spectrum. The significantly
reduced fertility of schizophrenia patients [87] indicates the presence of strong negative selection on
the trait, suggesting the disorder is a reasonable candidate for whole genome sequencing to identify
additional rare causal variants of large effect.
In light of limited budgets and finite sample sizes, the question of optimal study design is par-
ticularly pressing for rare variant analysis. Mere detection of variants with minor allele frequency
below 1%, or even 0.1%, requires genome sequences from many thousands of samples, which may
be impractical in many cases. Statistical power to detect significant association with an outcome
requires even more onerous sample sizes.
Most genetic analyses are formulated based on outbred populations, in which genetic diversity is
subject to certain steady-state characteristics: Hardy-Weinberg equilibrium, approximately constant
effective population size, fixation, etc. In the context of rare variants, recent bottleneck populati-
ons offer several possible advantages over outbred populations. Rare haplotypes from the source
population that happen to be sampled in the founders of the new branch may be disproportionately
overrepresented for many generations. In that time, over a limited number of generations and with
restricted mating, otherwise deleterious variation may be sustained at unusually high frequencies.
A multistage sequencing study was conducted in 349 schizophrenia cases and 225 controls, mat-
ched by Ashkenazi Jewish ancestry (though without further matching between cases and controls).
Limited sample size led to the application of rare variant burden testing, in the first attempt ana-
logous to published work in a similarly restricted context ([31]; Methods). While there is little
evidence for enrichment of functionally-annotated novel variation in schizophrenia cases, we detect
substantial evidence for stratification effects and cryptic relatedness correlated with disease status,
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Sites Novel alleles in cases Novel alleles in controls
Initiation codon 37 26 16
Loss of function 803 854 413
Protein-altering 7457 6625 3616
Synonymous 2981 2906 1571
Splicing 478 576 291
Stopgain 289 253 106
Table 4.1: Distribution of novel variants, partitioned by functional class from Variant Effect Predictor
(VEP) [90], out of 1.75 · 107 variants included in sequencing call dataset after full QC. Functional
category definitions are taken from [31]; note that VEP was used for their confirmation analysis,
which gave them results indistinguishable from their main results. Due to several indications of data
quality failures, indels are excluded from this analysis.
which is a function of both study design and burden test model. Taken as a whole, we provide
meaningful observations about the particular challenges of novel variant burden testing that are
informative to future sequencing study designs.
4.4 Results
4.4.1 Sample Characteristics
577 samples of Ashkenazi ancestry were sequenced using the Illumina X10 platform. This sample
includes one case and 27 controls that were either (1) IBS pˆi > 0.05 with another sample in the
study, or (2) included as duplicates of other sequencing samples, and were removed from downstream
analysis. After joint calling (GATK [88], New York Genome Center), variant quality filtering, and
additional stringency filters on segments annotated by the 1000 Genomes Project as problematic for
sequencing (Methods), the study contained approximately 1.75 · 107 variants across all frequencies.
After filtering for variants previously observed in 1000 Genomes Phase 3 [89], novel variants were
partitioned into groups based on functional annotation (Table 4.1).
4.4.2 Variant Quality Stratification
In the quality control process, affectation status was repeatedly observed as a significant predictor of
variant quality. Across all sequenced variants, without additional QC filtering beyond that performed
by the sequencing center, lower variant quality was significantly associated with higher minor allele
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Figure 4.1: Across the genome and in particular minor allele count bins, variant quality
is associated with schizophrenia outcome. X-axis: minor allele count bin (left most bar
corresponds to genome-wide signal, so all variants binned together). Y-axis: observed average
VQSLOD(cases - controls), with 95% confidence intervals representing the expected range under
the null according to 1000 permutations of outcome. Red bars correspond to bins (and whole
genome signal) with observed values outside the expected range. Under 61 tests, dubiously assuming
independence of count bins, expect 3 extreme bins, observe 13, pnull = 8.31 · 10−6. Variant quality
deviations at high minor allele frequency tend to correspond to Hardy Weinberg failures created by
artifactual sequencing results.
frequency in controls (Figure 4.1; case status-permuted p < 0.006). This additionally manifests as
significant deviations in pseudo-identity by state (IBS) relatedness in cases and controls (see Figure
4.2), such that controls appear much more strongly related within-class than cases (p < 0.00001).
This signal appears to be driven by the inclusion of poorly sequenced sites, creating a false IBS
signal that is correlated with outcome. Note that this pool of variants is expected to contain many
poorly-sequenced variants, and is not representative of the final callset; rather, we consider this
callset first to observe meaningful batch effects that may be obscured by later quality control.
Filtering variants to “PASS” quality reduces but does not abrogate this association. While
genome-wide variant quality is no longer associated with control frequency (Figure 4.3, p = 0.7),
variants with minor allele count less than 10 (corresponding to approximate minor allele frequency
< 0.01) still demonstrate this association (p < 0.004).
Applying additional filtering in this study according to the 1000 Genomes low confidence regions,
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Figure 4.2: Without variant filtering, spurious differential relatedness in samples corre-
lated with affectation status. Shown are histograms of pairwise IBS distributions within-cases,
within-controls, and between-status, including an LD-pruned subset of common (minor allele fre-
quency > 0.05) variants with no additional quality filtering. X-axis: pairwise (apparent) IBS; Y-axis:
number of sample pairs in IBS bin. Excluded from analysis are 27 controls and 1 case known to
be related. All distributions are significantly different from each other (PLINK IBS test method,
all p < 0.03, all but one less than 10−3). Note that due to the inclusion of sequencing failures,
these numbers do not represent true IBS signals but rather are predominantly sequencing errors
nonrandomly correlated between samples.
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Figure 4.3: Removal of non-PASS variants removes some but not all of the association
between VQSLOD and outcome. As in Figure 4.1, the X-axis depicts minor allele count bins
with the genome-wide signal represented in the left-most bar, while Y-axis is average VQSLOD(case
- control). The genome-wide signal is removed, as are many of the frequency bins, in particular
those at the highest minor allele counts that corresponded to strong Hardy-Weinberg equilibrium
violations. However, the signal at the lowest minor allele count bin remains (p < 0.004).
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Figure 4.4: Additional removal of 1000 Genomes pilot region variants removes the re-
mainder of unexpected association with schizophrenia outcome. X-axis: minor allele count
bins with genome-wide signal as left-most bar; Y-axis: average VQSLOD(case - control) within
corresponding bin.
which suffer from consistently poor sequencing quality, the noticeable case status/quality association
is finally removed (Figure 4.4). The pseudo-IBS association detected genome-wide is apparently
removed by the final tier of variant filtering (Figure 4.5); however, the between-group permutation
p-value for nonrandom clustering by affectation status is p = 0.061 in the same direction as the
original stratification effect, based as usual on independent common variants.
4.4.3 Novel Variant Stratification
Noting that uncommon variants selectively retained stratification signals through the QC process, we
specifically examine substrata of novel variants considered within this study for stratification signals
associating sequencing quality and disease status. Novel synonymous variants, used effectively as
loading controls in the Fisher testing in [31], show a strong within-class association between variant
quality and control frequency (Figure 4.6; p < 0.00135, upper 95% confidence bound on 100000
permutations). The subclass of novel variants annotated as “protein-altering,” a superset of loss-of-
function variants along with missense and stop-loss variants, show a similar association (p < 0.00045,
upper 95% confidence bound on 100000 permutations). No such association is detected in novel loss-
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Figure 4.5: With stringent variant filtering, differential relatedness in samples statisti-
cally uncorrelated with affectation status. Shown are histograms of pairwise IBS distributions
within-cases, within-controls, and between-status, after two stages of quality filtering. X-axis: pair-
wise IBS; Y-axis: number of samples in IBS bin. Excluded from analysis are 27 controls and 1 case
contributing to pairwise IBS pˆi > 0.05. Distributions are not significantly different from each other
(PLINK IBS test method, all p > 0.061.
of-function variants alone (p = 0.61).
We hypothesized that the stratification signal could be specific to individual contributing studies
within the 14 sets of controls submitted for sequencing, as opposed to within the two sets of cases.
To this end, we conducted within-outcome permutations of study labels, and tested for nonrandom
distribution of novel singleton quality ranking (so a non-parametric test on VQSLOD).
For novel loss of function variants, we do not observe a significant association between variant
quality rank and all group labels taken as a single categorical predictor (Kruskal-Wallis Rank Sum
p = 0.158), nor do we see nominally significant associations between quality and individual group
labels (all individual p > 0.05; though likely enriched for tests with p < 0.1, with such enrichment
p = 0.017). For novel synonymous variants, the group label categorical predictor is significantly
associated with variant quality rank (Kruskal-Wallis Rank Sum p = 0.0045), though once again no
individual group is significant (all permutation p > 0.05).
As VQSLOD is not an absolute metric but rather a complicated and difficult to interpret approx-
imation of variant quality, we also consider novel singleton call counts within contributing groups.
Note that the relationship between group VQSLOD and group singleton count is not unique, and
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Figure 4.6: Within novel variant annotation categories, significant association between
variant quality score and schizophrenia. In this case as opposed to prior figures, the X-axis
represents variant annotation category, while the Y-axis still represents average VQSLOD(case -
control) amongst variants in each class. Significantly higher VQSLOD in cases is detected for both
the protein-altering and synonymous categories (both p < 0.002).
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may have a variety of interpretations given the context. Furthermore, group singleton count re-
presents an abstraction that ignores missingness and uncertainty of underlying sequencing data by
introducing a confidence threshold that is then hidden from downstream analysis.
Considering novel loss of function variants, sample group is significantly associated with va-
riant count per sample (Kruskal-Wallis Rank Sum p = 0.003). Three individual groups are as-
sociated with aberrant mean rank amongst included individuals (Figure 4.7; from left to right,
p = 0.0194, 0.03194, 0.012; probability of observing three such results at α < 0.05 under null:
p = 0.043). Considering instead novel synonymous variants (Figure 4.8), sample group is again
associated with variant count per sample (Kruskal-Wallis Rank Sum p = 0.0088). Only one group
is significantly associated in the permutation test (red bar, p = 0.00072). In both cases, subcohorts
with significantly inflated counts correspond to groups that provided duplicates or related samples
to be sequenced; although samples were pruned before analysis to contain a maximal set of samples
unrelated at pairwise IBS pˆi < 0.05, the inclusion of these samples in sequencing has left a resi-
dual signal amongst novel variants that were presented to the sequencer and calling algorithm as
doubletons.
4.4.4 Residual IBS Stratification at Doubletons
We observed unusual behavior amongst novel doubletons. In conducting standard GWAS cryptic
relatedness sample filtering by IBS pˆi, we removed one case and 27 controls contributing to IBS
relationships with pˆi > 0.05, leaving as many samples as possible while still maintaining an apparently
pairwise-unrelated dataset. As expected, the 28 removed samples are substantially overrepresented
in doubletons in the unfiltered dataset (expected to randomly participate in approximately 9.5% of
doubleton pairs; observed 25% to 40%, depending on the functional subclass).
Amongst the 549 remaining samples, two cases and 24 controls were kept that were part of the
filtered IBS relationships; this is standard protocol for GWAS to maximize remaining sample size.
We observed that these individuals were overrepresented in novel singletons ascertained from the
filtered dataset (all p < 2 · 10−16). This is consistent with these individuals enjoying an aberrantly
high discovery rate when they are sequenced in duplicate but analyzed alone.
However, amongst doubletons discovered in the filtered dataset, we see large discrepancies in the
samples contributing to doubleton pairs. While the overall counts of doubletons amongst functio-
nal classes are reasonably consistent with expected counts of case/case, case/control, and control/
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Figure 4.7: Novel loss of function singletons show association between count and cohort.
X-axis: contributing cohort for sequencing; Y-axis: number of novel loss of function singletons.
Bars correspond to group means, while points correspond to individuals contributing to each co-
hort. Intervals represent approximate 95% confidence around expected group mean. Red bars are
groups with non-parametric permutation test p < 0.05; due to rounding and handling of ties, these
occasionally differ from the confidence intervals. Note that coordinates of points are jittered for
visibility, but in fact represent integral Y-axis counts. Overall Kruskal-Wallis Rank Sum test for
association between study subgroup and singleton count: p = 0.003; permutation test for association
in individual groups (for red bars only, from left to right: p = 0.0194, 0.03194, 0.012).
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Figure 4.8: Novel synonymous singletons show association between count and cohort.
X-axis: contributing cohort for sequencing; Y-axis: number of novel synonymous singletons. Bars
correspond to group means, while points correspond to individuals contributing to each cohort.
Confidence intervals are parametric 95% intervals around expected group mean. The red bar is
the group with non-parametric permutation test p < 0.05; while similar to the parametric test
denoted by the confidence intervals, they differ slightly and should not be confused. Note that
the coordinates of points are jittered for visibility, but in fact represent integral Y-axis counts.
Overall Kruskal-Wallis Rank Sum test for association between study subgroup and singleton count:
p = 0.0088; permutation test for association for the significant control subgroup p = 0.00072.
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Case/Case Case/Control Control/Control
Variants % Samples Variants % Samples Variants % Samples
Loss of function 26 13% 37 10% / 18% 13 10%
Protein-altering 192 66% 182 39% / 54% 73 49%
Synonymous 72 32% 73 19% / 30% 25 22%
Table 4.2: Distribution of novel doubleton variants, partitioned by functional class from Variant
Effect Predictor (VEP) [90]. Data are partitioned between doubletons involving two case samples,
two control samples, or one of each status. Percentages represent percent of individuals of a particular
disease status involved in at least one doubleton pair. All percentages are significantly lower than
expected assuming independent observations of doubletons (all p < 10−22).
control pairs based on the total number of called sites, each substratum excludes a large proportion
of the total set of possible interacting samples (Table 4.2). In all cases, the number of samples en-
tirely excluded from novel discovered doubletons is inconsistent with a discovery process randomly
sampling available individuals (all p < 10−22). This calculation assumes doubletons are discovered
independently of one another, which is invalid if this process is affected by long shared IBD segments
between individuals. In the presence of IBD, as expected in Ashkenazim, the effective number of
independent draws (discovered doubletons) will be lower. In order to make the observed percentage
coverage of individuals be consistent with random sampling, the sampling process must in fact be
independently discovering less than 10% of the total number of doubletons in order to generate good
fit of this model.
We considered whether individuals are equally likely to contribute to case/case or control/control
doubletons, respectively. We downsampled individuals from the case/case pairs to match the number
of unique individuals in the control/control subsets, and then observed the resulting number of
doubletons that would be discovered from such a set of cases. For all three functional classes
in Table 4.2, cases contribute significantly fewer doubleton variants per sample than controls (no
downsampled case sets discovered as many doubletons as the true control set, in 100000 attempts
for each functional class).
We finally investigated whether the observed pairs of individuals contributing to novel doubletons
exhibit nonrandom IBS relationships. IBS is computed from independent common variant distribu-
tions; yet we hypothesized that it might be a reasonable proxy for the IBD relationships considered
here. We thus took the observed distribution of IBS pˆi amongst novel doubletons, and compared it to
the distribution of IBS amongst the same doubleton set with permuted individual labels, stratified
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MAC Loss of Function Synonymous Normalized Fisher p-value
1 2.18 1.88 1.16 0.11
2 1.36 1.99 0.69 0.08
3 1.52 1.87 0.81 0.55
4 3.40 1.62 2.09 0.08
5 1.86 1.68 1.10 0.87
6 2.53 1.05 2.42 0.02
7 3.38 1.80 1.88 0.20
8 2.00 2.39 0.84 0.71
9 2.86 1.42 2.01 0.23
All 2.08 1.84 1.13 0.10
Table 4.3: Fisher and Cochran-Mantel-Haenzel summary data for loss of function ver-
sus synonymous novel variant discovery. Data represent relative enrichment in cases versus
controls. The “normalized” column refers to the ratio of the preceding two columns; values greater
than 1 indicate relatively more loss of function novel variants detected in cases than expected based
on synonymous baseline. MAC: minor allele count strata for CMH test.
by case status. Due to the heavily skewed distribution of IBS in the final QC set, we compare these
distributions using the non-parametric Wilcoxon rank sum test. Within the novel protein-altering
and synonymous variant subsets of doubletons, the distribution of IBS amongst paired individuals is
significantly higher than expected by chance (p = 0.0152 and p = 0.0449, respectively; 100000 per-
mutations of status-stratified sample ID). No significant deviation is detected for the loss of function
doubletons (p = 0.492).
4.4.5 Novel Variant Burden Testing: Fisher/CMH
The preceding results strongly suggest technical artifacts are interfering with novel variant discovery
in this sample. With this in mind, we consider skeptically a novel variant burden test in this study.
In addition to the Fisher test conducted in [31], we conduct a conceptually similar Cochran-Mantel-
Haenzel test (Methods) for contingency data, with case status and functional versus synonymous
alleles as the meaningful margins and minor allele count as confounding stratum. For novel loss-
of-function variants, there is no significant association between affectation status and allele burden
relative to synonymous control (p = 0.077; corresponding Fisher test ignoring allele count p = 0.103).
Loading of functional alleles between cases and controls is shown in Table 4.3.
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4.4.6 Novel Variant Burden Testing: GMMAT
In light of possible residual cryptic relatedness in this study, along with concerns about unusually
large segments of IBD in samples from bottleneck populations, we have investigated other burden
tests that specifically model intrasample correlations. A more extensive discussion of available
methods and limitations may be found in the Discussion; we show here the results of GMMAT [91],
which effectively fits a generalized linear mixed model (GLMM) testing per-individual case status
as a function of novel functional allele count. Note that under this model, novel synonymous allele
burden is not a significant predictor of case status (p = 0.63).
Considering loss-of-function variants, we find significantly increased burden of novel alleles in
schizophrenia cases (affectation-permuted GMMAT p-values, 10000 simulations (see Methods): p =
0.0059. This result considers the sample subset consisting of 549 samples with maximum pairwise
IBS of 0.05, and furthermore explicitly controls for the apparent genetic relatedness matrix amongst
reported-unrelated individuals as computed from pairwise IBS among common variants; however,
in practice, the results computed with GMMAT are not meaningfully different from those obtained
from the corresponding generalized linear model.
The functional category “loss of function” refers to the combined set of initiation codon, splicing,
and stopgain variants as annotated by VEP [90]. Among these subcategories, novel stopgain variants
are significantly enriched in cases (GMMAT permuted p = 0.0035); splice variants are not significant
but trending consistently (p = 0.06625); and there are insufficient novel initiation codon variants in
the sample, considering their distribution across 549 individuals, to draw meaningful within-class
conclusions (see Table 4.1).
4.4.7 Uncalibrated Type I Error Rates
Due to the limited publication history of the Fisher model for directly testing rare variant burden, we
investigated the behavior of various implementations of this model (Fisher/CMH, GLM, GMMAT
[91], EMMAX-CMC [92]) when testing the null burden of random rare variants. In particular, we
matched sets of exonic variants to the novel “loss of function” and novel “synonymous” categories
of rare variants by minor allele count, and used these subsets of variants to determine the empirical
null distribution of these tests. Note that the majority of novel variants in this study are singletons
(see Figure 4.9), and so to avoid complications involving mixtures of allele counts, we present results
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Figure 4.9: Distribution of minor allele counts across classes of variants. X-axis: minor allele
count bin; Y-axis: proportion of sample. Novel variants, in this case those specifically annotated as
“loss of function,” demonstrate a significantly higher proportion of singleton and generally low-count
variants relative to the genome-wide distribution. This is expected, as novel variants are a priori
expected to have lower frequency, in particular if subject to possible selective pressure.
exclusively for the singletons that constitute more than 80% of the matched variants.
Empirical null distributions are shown in Figure 4.10 for the Fisher test, as well as for the
generalized linear model equivalent used in this study. Testing random sets of frequency-matched
exonic variants, which should not be associated as a whole with schizophrenia, versus the true set of
novel synonymous variants generates a strongly inflated empirical null distribution. This inflation
is not specific to the novel synonymous control variants per se: replacing them with a fixed set of
frequency-matched exonic variants generates, depending on the particular draw, distributions with
a spectrum of inflation or deflation. Shown in Figure 4.10 is one particular distribution with an
inflation factor closely matching that observed with the true novel synonymous set. The magnitude
of inflation is specific to the Fisher model, but null inflation of a lesser magnitude is observed with
the GLM model as well (genomic control λ = 1.23, pnull = 0.0017).
Correctly calibrated null behavior is observed when the synonymous control set is resampled
with every simulation (Fisher: pnull = 0.7243; GLM: pnull = 0.2204). The precise reasoning behind
this behavior will be covered in the Discussion; for the moment, we simply report that some sort
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Figure 4.10: The null distribution of the rare variant testing model is inflated under
partial resampling. Shown are quantile-quantile plots (negative log10 scale) for three null models
for each of the Fisher test and GLM. Under the “syn control” model, a set of random exonic
singletons, matched in count to observed novel loss of function singletons, is tested for differential
burden versus the count of novel synonymous alleles in the sample. For the “fixed control” model,
both the loss of function and synonymous singleton sets are randomly matched in the exome, but a
single random synonymous-matched set is used as null control for each of the random loss of function-
matched sets. Finally, for “resampled control,” each functional-matched set is paired with a different
synonymous-matched set. The “fixed control” set shown here is selected from 1000 simulated sets
to present the inflation factor closest to the one observed in the “syn control” model; more extreme
inflation factors were observed and are not shown. The “resampled control” tests for both Fisher
and GLM are indistinguishable from random expectation under a true null model by inflation factor
(Fisher: p = 0.7243; GLM: p = 0.2204).
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of null resampling is required for desirable type I error behavior, and permutation of case/control
status will not correct this problem.
4.5 Discussion
In this study, we have undertaken a simple version of rare variant burden testing to find differences
in novel variant accumulation between schizophrenia cases and controls. The subset of novel variants
with “loss of function” annotations does not show significant differential loading between cases and
controls using a previously published method. We have detected and attempted to diagnose or
address as best as possible sample stratification, particularly in control samples, but it is open
to debate whether we can possibly control for such trait-associated technical effects within novel
variants, which are highly susceptible to sequencing errors.
The results of this study emphasize the importance of rigorous and consistent study design. At
its core and beyond any particular technical issues, the study intrinsically suffers from retrospective
trait collection. In the presence of such a limitation, it is of critical importance to enforce a strict
collection regime. Cases and controls are typically collected using some sort of matching regime,
often based on PCA (see, for example, [31, 93]). No such efforts were undertaken for this study, and
retrospective matching from the available samples will inevitably result in a serious loss of power.
One may suppose that this study design is the result of a desire to maximize sample count in the
context of realistic collection constraints. Yet in this situation, the lack of formal sample restrictions
has led to an outcome confounded by challenging stratification effects.
As the fixed synonymous control in the Fisher model appears to subject the test to an undesi-
rable Type I error rate under the null, we investigated other methods of representing the baseline
differential loading of alleles between cases and controls in the absence of disease effect. As shown
in Figure 4.11, the distribution of random exonic singleton alleles recapitulates the approximate
imbalance of cases to controls (actual ratio 1.74:1 in 549 samples). However, the loading of loss of
function alleles (shown as red line in Figure 4.11) is significantly higher than expected under this
null distribution (p < 0.01; similar imbalance observed in synonymous alleles). In effect, this is a
restatement of the result from the null Fisher test on this sample. However, with the knowledge that
the Fisher test has invalid asymptotic behavior within a single study, the offset of allele loading from
random exonic variants complicates the choice of a set of variants from which to resample a null set,
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Figure 4.11: Random rare exonic alleles match the case/control imbalance ratio. The
histogram of case/control loading bias amongst random exonic rare variants is depicted. The dis-
tribution is consistent with the true case:control ratio of 1.74:1 (blue line). The subset of novel loss
of function alleles (red line), however, are overrepresented in cases at a ratio of 2.07:1 (significantly
higher than expected under null loading, p < 0.01).
as one must find sets of variants that have equivalent error distributions in cases and controls.
We find evidence in Figure 4.7 and Figure 4.8 that inclusion of related and duplicate samples
in sequencing is more complicated than we originally considered. The initial analysis plan for this
study followed the plan for an analogous common variant association study, at least as regards cryptic
relatedness. As a first approximation, we pruned the sequenced dataset to contain only samples with
pairwise IBS pˆi < 0.05, corresponding to second cousins, and considered these remaining samples
as approximately unrelated. However, we removed the minimum possible number of samples to
maintain the maximum downstream power while maintaining the unrelatedness constraint. We thus
left in several dozen samples that contributed to the original relatedness pairs. What we observe is
that these leftover samples retain a significant inflation in call rate at novel singletons, as these most
challenging variants are provided with double evidence during the sequencing process. As is the case
with all stratification signals we detect in this study, it is difficult to quantify the precise effect this
signal will have on downstream analysis. The inclusion of relateds in this study was not random
with regards to outcome: the vast majority of related samples were controls. We therefore cannot
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assume that any associated effects will “average out” across the association test. An appropriately
constructed burden test may be able to control for these call rate differences, but will likely have
to assume that the impact of relatedness on call rate impacts all novel exonic variation to an equal
degree. Any deviation from this assumption will induce an artifactual association between outcome
and variant burden that cannot be controlled without additional validation sequencing, to which we
do not have access.
The above observations about sample-wide relatedness and its impact on sequencing raises ad-
ditional questions about the impact of nonrandom local identity-by-descent (IBD) present in either
cases or controls. In individual regions with IBD segments, one would expect recent mutations to
have higher sequencing quality due to the inclusion of the mutation in multiple samples. While
the sequencing technology, as deployed in this study, does not explicitly accommodate IBD into its
calling algorithm, additional copies of a variant will still have some impact within the IBD region.
In many contexts these local improvements in call rate will either be (1) undetectable due to the
high sequencing quality on common variants in the region, or (2) unconditionally advantageous as
the result is simply better sequences. However, in the specific context of small-sample rare variant
burden testing, one could reasonably construct a model in which nonrandom partitioning of IBD
segments between cases and controls, or within control subgroups, or between classes of functional
variants, could lead to artifactual trait associations. We mention this concern as a possible point
of consideration for future sequencing studies: relatedness should either be formally addressed or
confirmed to be uniformly distributed a priori.
A surprising observation during this analysis is the extent to which this study design, beyond
technical artifacts from non-randomization, is fundamentally incompatible with existing statistical
models. The possible presence of trait-associated variant quality and cryptic relatedness introduces
the problem of conducting regression on a binary trait in the presence of an arbitrary and informative
correlation structure.
The Fisher and Cochran-Mantel-Haenzel tests interrogated in this study assume independence
of observations in all bins. This assumption is maintained in all major alternative methods for
analysis of contingency data. Deviations from independence can typically only be accommodated
in cases of structured dependency, such as paired sampling [94]. Furthermore, as we have seen, the
CMH and Fisher tests require a resampled null distribution of variants for each independent burden
test conducted, which is challenging to accomplish in the specific context of novel variation with
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stratified sequencing performance between cases and controls.
The most obvious alternative to contingency testing is the use of regression. The standard
model for association between predictors and outcomes in the field is obviously the generalized
linear model (GLM). As this ad hoc burden test does not sum across individuals, the requirement
for a null sampling of variants representing the imbalance between cases and controls in the study is
removed. The GLM is effective in the case of independence of samples, but has no means of modeling
sample clustering: specifically, the likelihood being fit in this model is only formally guaranteed to
exist in the case of independence of samples [95]. Depending on the particular sample structure,
standard regression may still perform well, but this is not a reliable outcome. In the case of our
sample, we have a dataset with several dozen IBS-related samples primarily in controls; even with
these particular samples removed, we are left with a sample from a bottleneck population that will
have higher inter-sample correlation than is usual amongst population studies. Alternatives that
explicitly handle inter-sample correlation are desirable.
Generalized least squares (GLS; not to be confused with GLM) offers the opportunity to extend
regression to a correlated dependent variable. An implementation of generalized least squares that
handles arbitrary correlation structure exists in R [96]. Unfortunately, GLS (in spite of the name)
assumes a normally-distributed outcome. Alternatively, in MATLAB, an implementation of GLS
can handle a binary dependent variable, if the mean and variance functions of the fit are specified
to fit the logit function [97]. However, these two options are not combined in any existing general
implementation, as far as we can determine. The primary concern is simply that the introduction
of the nonidentity link function introduces dependency between the mean and variance estimators
in the model.
Taking a different approach, we might consider traditional models for handling clustered (or
equivalently longitudinal) data analysis. The two primary methods of handling clustered binary
data in regression are generalized estimating equations (GEE; [98]) and generalized linear mixed
models (GLMM; [99]). The choice of model primarily depends on the desired interpretation of the
estimated parameters, either marginalized over random effects or conditional to them. Regardless of
this particularity, the introduction of correlation structures takes place through the random effects
parameters in both models. These take the form of categorical clustering variables, which partition
the samples into subunits. Correlation is modeled within these clusters, whereas samples between
clusters are still assumed to be independent; the algorithms then typically have asymptotic guaran-
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tees dependent on the number of clusters [100]. Under structured pedigrees, these clusters could be
approximated by family unit; however, in the case of unstructured cryptic relatedness, there is no
easy partitioning.
Moving beyond general-purpose models, the primary in-field method for handling cryptic rela-
tedness in association studies is the EMMAX software package [56]. This software confronts the
computational complexity of deploying a full GLMM on whole-genome variant data by isolating a
single variance component based on pairwise IBS estimates. EMMAX offers the notable distinction
of not requiring cluster data as full GLMM does; rather, it computes the variance component cor-
responding to the provided covariance structure, and then conducts ordinary least squares on the
result. This method has numerous similarities to GLS.
Although the initial release of EMMAX was closed source, it has since been integrated into an
open-source genomics pipeline EPACTS [92]. From that source, and from the EMMAX paper [56],
we find that variant burden testing on binary outcomes is apparently possible. However, inspecting
the source code, we find the following:
 EMMAX does not directly support binary traits, they are treated as normal traits; and
 EMMAX does not explicitly support covariates; rather covariates are combined with the kins-
hip matrix and are then simultaneously regressed out of the outcome
It would be exceedingly convenient to ignore normality of response variable for this analysis. The
EMMAX paper loosely cites Armitage [101] to justify this behavior; among the canonical citations
for the need to formally model binary outcomes with appropriate linker functions is [95]. It would
seem that using an unrestricted continuous linear combination to estimate a binary response with
dependent variance is a rather serious offense, as argued in [91] in particular for EMMAX.
Addressing the particular concern of EMMAX-style association analysis on retrospectively ascer-
tained case/control traits without violating distributional assumptions is a topic of active research,
falling vaguely into three categories, according to the general class of solution employed.
The software CARAT [102], as well as its predecessor from the same group, ROADTRIPS [103],
and its successor CERAMIC [104], use a custom specification of estimating equations (analogous to
GEE) in order to incorporate a genetic relatedness matrix as a correlation structure. The primary
difference between the packages involves covariate and missing data handling. While these options
may well be an adequate substitute for EMMAX for single SNP association, the underlying test
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statistic is a score test derived specifically for single SNP testing. The model particularly assumes
Hardy-Weinberg distribution of alleles and biallelic SNPs. While the authors cite a generalization
for multiallelic SNPs [105], sums of rare events strongly violate the model’s distribution assumpti-
ons; furthermore, stratification effects, such as the differential cryptic relatedness brought about by
sequencing errors observed in this dataset, are not addressed [106].
As CARAT/ROADTRIPS are genomics-specific variants of GEE, so the software GMMAT [91]
extends GLMM into the genomics problem of sample-wide correlation estimated from a relatedness
matrix. While the underlying model is distinct, GMMAT suffers from the same limitations as
CARAT: statistical tests run under this model strongly assume common biallelic SNP behavior, and
do not address nonrandom relatedness correlated with affectation status. We have deployed this
method in this study as it is minimally feasible to run, a trait not shared by all of its competitors.
We have adopted extensive permutations to generate empirical p-values; however, this process is
extremely computationally intensive, and does not necessarily address all the structural problems
present in the dataset. Furthermore, upon actually deploying this model, we find that the results are
effectively indistinguishable from those of GLM. At least from the perspective of common variant
IBS as a proxy for sample correlation, there is no significant impact of sample correlation on this
study’s burden test association. There may well be more subtle methods of specifying correlation
structure based on the effects specific to rare variant sequencing quality that we observe, but in the
absence of signal and preponderance of evidence of technical artifacts, we have not undertaken this
effort.
Finally, in order to provide a complete picture of the state of the field, the LTSOFT package [107,
108, 109, 110] purports to address retrospectively collected binary trait association in the presence
of arbitrary cryptic relatedness and biased relatedness sampling. Using epidemiological parameters
specific to each individual trait analyzed, this model computes an expected (normally distributed)
liability distribution underlying the trait. The resulting distribution is used as a normal outcome
in standard, relatedness-aware LMM. In theory, if such a distribution could be reliably computed,
it would be straightforward to run a burden test under LMM with variant burden as a standard,
arbitrarily distributed quantitative covariate.
Unfortunately, several limitations prevent this model from being deployed in the context of the
current study. It is difficult to judge the quality of software released so recently, yet LTSOFT (in
its implementation, called LTFAM, designed to address nonrandom relatedness sampling) seems to
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suffer from serious issues. Even the example data provided as a simple demonstration of the software
run with errors, on multiple platforms. More seriously, both the example run and a test run on the
schizophrenia dataset from this study report a grievous issue: the posterior mean liability (Fam-
PML, in the software’s parlance), which is the normally distributed liability distribution used as the
outcome in the final LMM, is effectively still binary. In the case of the example file, the case/control
data have been transformed from placeholder numbers {1, 2} to rescaled numbers on (for cases)
[2.32, 2.34] or (for controls) [−0.04,−0.02]; similar results are observed for the schizophrenia data.
The non-normal distribution of the expected liability values for the dataset suggest a more
fundamental issue at work: the liability distribution will only be informative and smooth when
adequate numbers of clinical and genetic predictors are applied to the model. In the case of the
current schizophrenia dataset, no clinical predictors are available; the only non-genetic parameter
with discriminatory power is apparent SNP-sex, with 1.4X disease likelihood in men. Providing a
more complex model involving a large number of genetic predictors may yield a more reasonable
liability distribution. Yet even under this model, issues remain. The epidemiological data used by
the software is specified to be disease prevalence within bins of epidemiological predictors: in other
words, prevalence of disease in individuals of age 35–45, or individuals of high cigarette consumption,
etc. Unfortunately, example files with the software, when compared to the citations given for them,
provide conflicting evidence of whether the software should in fact use prevalence data; or rather
incidence data, as is included in several instances; or instead some other form of data, as several
of the citations did not include the reported data at all. That these files were cited as specifically
those used by the developers in [107] is additionally troubling.
In brief, we see no existing method for formally correctly handling a study design such as has been
retrospectively determined in this study. From a certain perspective, it is inappropriate to blame the
statistical models available for the failure to handle this analysis. Study design is an established field
and has significant theory and tools available. Ignoring them during sample collection is standard
enough in statistical genetics, but introduces predictable problems further on. We may consider this
dataset to simply have a fundamental flaw that prevents it from being used for case-control analysis
of novel variants.
This analysis raises serious questions about the validity of the Fisher test results from [31]. The
evaluation of the null behavior of the statistical tests in Figure 4.10 reveals a flawed assumption at
the core of the model deployed in the previous study. Asymptotically, the novel synonymous variant
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control provides an appropriate representation of the null distribution of novel variants in a study.
However, the relevant asymptote is based on repeated sampling of novel synonymous variants across
multiple studies, and furthermore this asymptote is obligatory and does not extend to reasonable
behavior in a single cross-section. Within an individual study, the observed ratio of case novel
synonymous variants to control is a fixed sample from an error distribution around the conceptual
true mean ratio. The deviation of the observed value from the unknown underlying mean value
(approximately number casesnumber controls ) corresponds to a consistent directional bias in every Fisher/CMH
test using this model within a single study.
In practice, this means that for a given functional variant class, we should expect the results
of many different studies to behave correctly under the null; yet within a single study, multiple
functional variant class tests using a single null will exhibit systematic null inflation or deflation,
depending on the precise parameters (sample size, case/control imbalance, sequencing quality stra-
tification between cases and controls, direction of observed loading of particular functional class)
in a particular study. We note that the novel synonymous allele ratio observed in [31] is indeed
depleted in cases relative to the actual case count, meaning all of the results from the study are
likely anticonservatively biased and correlated.
Furthermore, the study in [31] provides no formal analysis of cryptic relatedness. Cryptic related-
ness is, to some degree, a feature of all genetic studies. However, the nature of bottleneck populations
leads to a much more substantial degree of sample relatedness between otherwise distinct families. In
other contexts, this relatedness is actually beneficial [111]; however, especially in the context of small
sample sizes (45 cases, 53 controls for the study in question), specific controls must be implemented
to prevent meaningful stratification gradients that correlate with disease outcome. The reference
Alzheimer’s study makes no mention of quality control assessment of cryptic relatedness, and cases
and controls were ascertained separately with matching on the first two principal components.
While none of these results directly contradict the results of [31], they raise substantial questions
about the reliability of the study. It is possibly trivial to point out that these issues and many more
are, in the end, why it is traditionally considered inappropriate to conduct biological tests on tiny
sample sizes using nonstandard statistical models. Nevertheless, the fact that this schizophrenia
study, five times larger than [31], is subject to numerous confirmed stratification and batch effects
shows once more that the sample sizes required to wash away concerns about informal study design
are quite large in the context of human genomics.
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4.6 Conclusion
We conduct rare variant discovery in a sample of Ashkenazi schizophrenia cases and controls. Limited
by sample size, we investigate the case burden of novel loss of function variation. In lieu of a strong
biological signal, we find substantial evidence for stratification effects in the set of novel variants,
impacted in part by both sequencing quality and identity by descent. As relatedness was not a
priori accounted for during the design of this study, any novel variant discovery test is likely to be
fundamentally confounded by differential variant discovery rates in regions of IBD, so long as any
heterogeneity exists between cases and controls.
The impact of IBD on variant burden and discovery has certainly been considered previously, even
particularly with Ashkenazim [112]. However, in prior contexts, this sharing has been considered a
benefit, as it could potentially enable long-range imputation or inference. Here, we see the potential
for the introduction of confounding effects, in particular in small samples, when insufficient matching
is performed between cases and controls. Of particular note is the signature left on samples even
after GWAS-style post hoc IBS filtering is performed. These results, beyond considerations for the
present study, may inform proper sequencing study design moving forward.
4.7 Methods
4.7.1 Sample Characteristics and Sequencing
574 individuals of Ashkenazi Jewish ancestry were sequenced on the Illumina X10 platform. This
corresponds to 349 cases and 225 unmatched controls. The samples were jointly called by the New
York Genome Center using GATK [88]. Standard PASS quality control calls were generated for
variants with variant quality score log-odds (VQSLOD) less than −1.9403 (for single nucleotide
polymorphisms) or −0.7365 (for insertions and deletions). Additional quality control was applied
by collaborators by removing variants in genomic regions with the following filters:
1. remove SNPs in masked and low complexity regions
2. remove SNPs with VQSLOD < −2 in 1000 Genomes “pilot” regions
3. remove SNPs with VQSLOD < −2.5 in 1000 Genomes “strict” regions
4. remove SNPs with greater than 10% missingness across all samples
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Furthermore for the purposes of this analysis, all insertions and deletions were removed from
consideration.
4.7.2 Cryptic Relatedness
Apparent sample relatedness was computed using pairwise IBS computed in PLINK [49]. For this
analysis, rare variants (minor allele frequency less than 1%) were removed, and remaining common
variants were pruned by pairwise LD to reach approximate independence. Permutation testing
for IBS stratification by affectation status was implemented manually due to discrepancies in the
corresponding function in PLINK.
4.7.3 Variant Quality Stratification Testing
Testing for stratification of variant quality by affectation status was conducted by permutation
testing on case/control labels. Within substrata (uncleaned data, PASS only, full QC only, clean
novel functional SNPs only, etc.) frequency differentials were computed in 50000 permutations; only
549 samples with IBS pˆi < 0.05 were included in this analysis. Reported p-values are worst-case
upper 95% confidence intervals on the estimated binomial distribution parameter according to the
“binconf” module in the R Hmisc package [113].
4.7.4 Sequencing Call Rate Stratification Testing
Testing for stratification of call rate (or count) by contributing cohort was conducted by permutation
testing on cohort label within case/control status. Permutation two-tailed p-value indicates the
probability of observing as extreme a count in the same number of individuals randomly sampled
from same outcome. P-value is from 10000 permutations; only 549 samples with IBS pˆi < 0.05
were included in this analysis. Reported mean counts were computed from observed samples; 95%
confidence intervals were based on observed counts from permutations. Confidence intervals and
nominal p-values do not perfectly coincide due to permutation approximations and the assignment
of ties.
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4.7.5 Novel Variant Selection
Following the analysis plan of [31], we selected variants for burden testing as follows. Variants had
to be observed within the post-QC Illumina dataset amongst 549 IBS-unrelated individuals. Novel
variant determination was based on prior observation of variants in 1000 Genomes Phase 3 [89].
Sequencing QC removed multiallelic variants, and due to additional concerns about stratification
effects, indels were excluded from analysis. The frequency filter applied in [31] was relevant for
their analysis due to limited sample size in their centenarian cohort; in this larger dataset, novelty
made the 2% threshold redundant, as all variants with more than 20 minor alleles were previously
observed.
4.7.6 Functional Annotation
The Ensembl Variant Effect Predictor [90] was used to generate functional annotations. Loss of
function was defined as the union of the annotations “splice acceptor variant,” “splice donor variant,”
“splice region variant,” “start lost,” and “stop gained.” Synonymous controls were defined as vari-
ants of the same annotation. Protein-altering variants included all loss of function variants, along
with “missense” and “stop lost” annotations; however, due to apparent strong association between
variant sequencing quality and affectation status within this category, association results were not
considered reliable and are not presented.
4.7.7 Fisher and Cochran-Mantel-Haenzel Tests
We test independence between schizophrenia case status and functional variant burden over non-
functional variant burden with a Cochran-Mantel-Haenzel test [114]. Specifically, we test for in-
dependence conditional on the number of nonreference alleles present within the dataset for each
variant. We conduct the analogous marginal Fisher test, summed across minor allele counts on
[1, 10], for comparison. To further address possible convergence issues with these tests, we permute
case status 104 times and recompute p-values from the resulting bootstrapped distribution.
The Cochran-Mantel-Haenzel is effectively a dimensional extension of the Fisher test from [31];
we chose this method when substantial minor allele count-specific effects were observed to be corre-
lated with relatedness between samples. For consistency, the CMH test assumes both independence
of observations and homogeneity of effect within frequency strata: this is also interpretable as no
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three-factor (affectation/functional/frequency) interactions, or odds ratios indistinguishable at in-
distinguishable at different levels of minor allele count. Testing for validity of these assumptions was
conducted with IBS analysis (for independence) and the Breslow-Day statistic (for homogeneity of
effect) ([114], implementation from [115]).
4.7.8 Extended Models of Burden Testing
Due to concerns about sample cryptic relatedness and informative stratification, which may be
of particular concern for founder populations [116], we consider more flexible models for burden
analysis that consider sample correlation structure. A thorough evaluation of existing methods and
their limitations may be found in the Discussion. We highlight two methods for which we present
results here.
EMMAX/EPACTS
The EMMAX software package [56] is widely used for handling cryptic relatedness in population-
based samples for quantitative traits. Though the base package does not provide options for burden
testing and is closed source, a modified version of the software has been incorporated into the
software pipeline EPACTS [92]. We use the “emmaxCMC” collapsing test with per-individual novel
synonymous allele count as covariate. It is important to note that both EMMAX and emmaxCMC
treat a binary trait as a normally distributed, continuous outcome. Also note that in the Fisher-
style analysis, synonymous allele count was acting both as a control for unbalanced design and for
nonuniform sequencing efficiency between samples, whereas in this regression model it serves as a
control only for the latter.
GMMAT
Among the available tools for directly handling binary trait association in the presence of stratifica-
tion, we have selected GMMAT [91] due to feasibility and ease of use. GMMAT is an implementation
of generalized linear mixed models with external covariance matrices specified for arbitrary numbers
of random effects. We conduct affectation status permutations to generate empirical p-values, using
the same regression model used in EMMAX/EPACTS. Note that this process takes several days for
a single association test with permutations, and is not suitable for deployment in larger studies of




Genome-wide association studies have provided the foundation for the last decade of human statis-
tical genetics. The rapid expansion of this study model has led to certain methodological simplifi-
cations that provide fertile ground for improvement. Here, we consider complications of traditional
variant association, and examine ways in which GWAS conventions may be formalized or improved.
First, we provide the most extensive proof available of the inherent reliability of the quantitative
trait GWAS model, and elaborate precisely what confounding factors lead to apparent difficulties
in replication of GWAS signals. Second, we consider the handling of missing and uncertain data in
genotype imputation, which can be improved to increase statistical power to detect association with
minimal effort and no additional sample collection. Finally, we provide formal statistical analysis of
novel variant detection in a bottlenecked population, and elaborate on several confounding effects
specific to novel variation that have not previously been appreciated in the literature. Overall, this
work offers substantial improvements to GWAS methods across the entirety of the study model.
We begin by confronting the profound lack of formal evaluation of the performance of quanti-
tative trait GWAS. We collect all replication data across the entire field, and apply a rigorous and
standardized replication scheme, most notably correcting for the Winner’s Curse in variant discovery.
While it is now standard for GWAS papers to provide internal replication of discovered variants,
the majority of publications fail to publish sufficient data to allow independent verification of their
claims. Amongst the minority of papers that do provide proof of replication, unmatched ancestry
between discovery and replication, as well as incorrect reporting of per-variant sample sizes reflecting
the true rate of missingness at each variant, is sufficient to explain all aberrant replication rates. In
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contrast to much public perception, we find and prove the field to be fundamentally reliable, and
provide a simple tool for applying existing Winner’s Curse correction methods to users’ GWAS data.
We proceed to consider the appropriate handling of uncertain genotype data in association stu-
dies. The field at large employs several techniques for incorporating probabilistic genotypes into
statistical tools, yet these tools ignore validated and formally correct method for uncertain data
handling, Multiple Imputation, used in the statistical literature for decades. In part, this oversight
is likely due to the inconvenience of modifying existing statistical tools to use MI; as such, we create
a simple tool that creates an interface between GWAS tools and MI, removing the majority of the
labor involved from the user. We show that using MI can substantially improve detection of true
signals even in the context of underpowered studies, by correctly and explicitly introducing a variant
component describing the variability in association effect introduced by genotype uncertainty.
In light of the Missing Heritability problem, the field has dedicated vast resources to the collection
and study of rare variants; thus we investigate rare variant association with schizophrenia in a
bottleneck population. As is altogether too often the case, we find that the study design flaws of
standard GWAS magnify when considering specifically novel variation. Cryptic relatedness and IBD
sharing between samples may lead to aberrantly high call rates of novel singletons once the standard
post hoc relatedness filter is applied to samples. If cases and controls are nonrandomly sampled
relative to these stratification effects, as is the case in this study, the resulting incidence rate of
novel variation cannot be compared between groups. Furthermore, simple methods of adjusting for
baseline novel variant discovery rate in samples, such as the Fisher test, must be carefully applied:
the use of a single set of reference variants introduces correlated errors into downstream burden
tests. Overall, we find that subtle deviations from random sampling, which may often be ignored in
common variant GWAS, lead to irreparable flaws in the specific context of rare and novel variant
burden tests.
While these studies have provided a substantial improvement to GWAS methodology, numerous
issues remain. The Winner’s Curse correction data only represent quantitative trait GWAS; there
remains the unlikely possibility that the reliability of quantitative trait GWAS is specific to this
subset of the field; the tools created for this study are immediately extensible to binary trait GWAS
results, and merely await the appropriate data collection. Multiple Imputation can only provide so
much benefit: it is ultimately restricted by the quality of the underlying probabilities generated by
genotype imputation. Yet we have shown that such genotype probabilities are themselves incorrect
98
and biased in a predictable fashion. This issue may be addressed either by improvement of the
imputation software by the appropriate investigators, or by creating a formal post hoc correction
model for this bias, which would require a large pool of GWAS datasets to encompass all relevant
parameters. Finally, these developments have provided reasonable improvements to several aspects
of the GWAS model, but have not directly addressed the absence of expected explained genetic
variance, arguably the most serious issue confronting the field. Rather, the replication project
in particular has addressed certain issues raised about the fundamental viability of the field, and
other investigators have shown that there remains substantial causal genetic variation that may be
unlocked by truly colossal sample sizes. Yet there remains missing heritability, and no matter how
wedded the field is to single variant association, at some point the challenge of arbitrary genome-wide
epistasis testing must be addressed.
For this project we have chosen several particular GWAS vignettes to which to apply rigorous
study, yet the GWAS model is complex and ever-growing. So long as the drive to produce GWAS-
style results continues to expand, the field will continue to suffer from simplifications and oversights:
there simply are not sufficient statistical and computational resources to address the cornucopia of
study designs and challenges in GWAS. More narrowly, there is limited utility in providing compu-
tational tools and statistical solutions to problems in any biological field. The most difficult step
remains, as ever, unaddressed: the tools and expertise must spread to investigators actually con-
ducting these studies. This requires a combination of wise and user-friendly software design, as
well as successful dissemination of the tools and their benefits. In the context of GWAS, the latter
concern typically leads to tools only being adopted if they are developed by researchers attached to
labs running large-scale GWAS meta-analyses. This is not in any way a judgment of the value of
such tools, but it nevertheless leads to difficulties in producing tools in detached computational labs.
It remains the case that the most fruitful study will be conducted by biologists and informaticians
in close collaboration, each informing the others’ research.
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